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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 06, Revision 4 
(FGE.06Rev4): 
Straight- and branched-chain aliphatic unsaturated primary alcohols, 
aldehydes, carboxylic acids and esters from chemical groups 1, 3 and 41
EFSA Panel on Food Contact Materials, Enzymes,  
 Flavourings and Processing Aids (CEF)
 
2, 3
European Food Safety Authority (EFSA), Parma, Italy 
  
This scientific output, published on 19 March 2013, replaces the earlier version published on 20 
February 2013.4
ABSTRACT  
 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 56 flavouring substances in the Flavouring Group Evaluation 6, Revision 4, 
using the Procedure in Commission Regulation (EC) No 1565/2000. This revision is made due to the inclusion of 
six additional flavouring substances, (-)-3,7-dimethyl-6-octen-1-ol [FL-no: 02.229], dec-4(cis)-enal [FL-no: 
05.137], neral [FL-no: 05.170], trans-3,7-dimethylocta-2,6-dienal (geranial) [FL-no: 05.188], trans-3-hexenyl 
formate [FL-no: 09.562] and cis-3-hexenyl 2-methylbutanoate [FL-no: 09.854]. None of the substances were 
considered to have genotoxic potential. The substances were evaluated through a stepwise approach (the 
Procedure) that integrates information on structure-activity relationships, intake from current uses, toxicological 
threshold of concern and available data on metabolism and toxicity. The Panel concluded that the 56 substances 
[FL-no: 02.125, 02.138, 02.152, 02.170, 02.175, 02.176, 02.195, 02.201, 02.222, 02.229, 02.234, 05.061, 
05.082, 05.137, 05.143, 05.170, 05.174, 05.188, 05.203, 05.217, 05.218, 05.220, 05.226, 08.074, 08.100, 
08.102, 09.341, 09.368, 09.377, 09.562, 09.567, 09.569, 09.572, 09.575, 09.612, 09.638, 09.640, 09.643, 
09.672, 09.673, 09.674, 09.831, 09.838, 09.854, 09.855, 09.871, 09.872, 09.884, 09.885, 09.897, 09.898, 
09.928, 09.937, 09.938, 09.939 and 09.950] do not give rise to safety concern at their levels of dietary intake, 
estimated on the basis of the MSDI approach. Besides the safety assessment of these flavouring substances, the 
specifications for the materials of commerce have also been considered. Adequate specifications including 
complete purity criteria and identity for the materials of commerce have been provided for all 56 candidate 
substances. 
© European Food Safety Authority, 2013 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2012-00683, EFSA-Q-2012-00684, EFSA-Q-2012-
00685, EFSA-Q-2012-00686, EFSA-Q-2012-00687, EFSA-Q-2012-01013, adopted on 30 January 2013. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenco, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Catherine Leclercq, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de 
Fatima Tavares Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine 
Husøy, John Christian Larsen, Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific 
opinion and the hearing experts: Vibe Beltoft, Pia Lund, Karin Nørby and EFSA staff: Kim Rygaard Nielsen for the 
support provided to this scientific opinion. 
4 Editorial changes have been made to pages 1 (requesting party), 7 and 8 (History of the Evaluation) and to tables 5, 6 and 7 
(double bonds in chemical structures). The changes do not affect the overall conclusions of the scientific opinion. 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 56 flavouring substances in the 
Flavouring Group Evaluation 06, Revision 4 (FGE.06Rev4), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 56 straight- and branched-chain unsaturated 
primary alcohols, aldehydes, carboxylic acids and esters belong to chemical groups 1, 3 and 4, Annex 
I of the Commission Regulation (EC) No 1565/2000. 
The present revision of FGE.06, FGE.06Rev4, includes the assessment of six additional flavouring 
substances, (-)-3,7-dimethyl-6-octen-1-ol [FL-no: 02.229], dec-4(cis)-enal [FL-no: 05.137], neral [FL-
no: 05.170], trans-3,7-dimethylocta-2,6-dienal (geranial) [FL-no: 05.188], trans-3-hexenyl formate 
[FL-no: 09.562] and cis-3-hexenyl 2-methylbutanoate [FL-no: 09.854]. 
Ten of the substances possess a chiral centre [FL-no: 02.170, 02.175, 02.229, 05.143, 09.341, 09.612, 
09.854, 09.871, 09.872 and 09.938]. Thirty-eight candidate substances can exist as geometrical 
isomers [FL-no: 02.152, 02.195, 02.222, 02.234, 05.061, 05.082, 05.137, 05.170, 05.188, 05.203, 
05.217, 05.218, 05.220, 05.226, 08.074, 08.102, 09.377, 09.562, 09.567, 09.569, 09.572, 09.575, 
09.638, 09.640, 09.643, 09.672, 09.673, 09.674, 09.831, 09.838, 09.854, 09.855, 09.884, 09.885, 
09.928, 09.937, 09.939 and 09.950]. For all substances, the stereoisomeric composition has been 
specified. 
Fifty-four of the substances are classified into structural class I and two substances [FL-no: 05.143 
and 09.884] are classified into structural class II according to the decision tree approach presented by 
Cramer et al. 
Forty-one of the flavouring substances in the present group have been reported to occur naturally in a 
wide range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when 
the Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 54 flavouring substances belonging to structural class I 
have intakes in Europe from 0.0012 to 1600 µg/capita/day, and for the two substances from structural 
class II the intakes are 0.12 and 0.58 µg/person/day. These intakes are below their respective 
thresholds of concern value for structural class I and II of 1800 and 540 µg/person/day, respectively. 
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On the basis of the reported annual production volumes in Europe (MSDI approach), the combined 
intake of the 54 candidate substances belonging to structural class I and of the two candidate 
substances belonging to structural class II would result in a total intake of approximately 2900 
µg/capita/day (corresponding to 48 µg/kg bw/day) and 0.7 µg/capita/day, respectively. While the 
value for structural class II is below the threshold of concern for class II substances of 540 
µg/person/day, the value for the structural class I is above the threshold of concern for class I 
substances of 1800 µg/person/day. The total combined estimated intake of 87 of the 92 supporting 
substances for which European annual production data are available and of the 54 candidate 
substances from structural class I is approximately 17200 µg/capita/day (corresponding to 
approximately 0.3 mg/kg bw/day) which is 200 times lower than the NOAEL of 60 mg/kg bw/day for 
the supporting substance citral, obtained in a 2-year carcinogenicity study in mice. Most of the 
estimated combined intake of candidate and supporting substances would originate from intake of 
geraniol, nerol, citronellol, rhodinol and their esters together with geranial, neral and citral. The Panel 
noted that the JECFA has evaluated citral at several occasions together with geranyl, neryl, citronellyl 
and rhodinyl esters and have allocated a group ADI of 0 - 0.5 mg/kg bw/day, expressed as citral for 
citral, citronellol, geranyl acetate, linalool and linalyl acetate. The estimated combined intake would 
not exceed this group ADI. The Panel concludes that at the level of exposure resulting from the use as 
flavourings, all the candidate and supporting substances are expected to be efficiently metabolised 
and would not be expected to saturate the metabolic pathways. For these reasons and in the light of 
toxicological data on supporting substances, the total combined intake of these substances would not 
be expected to be of safety concern. 
For the substances in this group the data available do not give rise to safety concern with respect to 
genotoxicity and carcinogenicity.  
Except for hex-3-enyl 2-ethylbutyrate [FL-no: 09.884], the candidate substances are expected to be 
metabolised to innocuous products at the estimated levels of use as flavouring substances. One of the 
hydrolysis products of [FL-no: 09.884], 2-ethylbutyric acid, showed teratogenic potential in one 
mouse subcutaneous single-dose study, and is structurally related to valproic acid, which is a known 
teratogen. However, an additional study in which 2-ethylbutyric acid was given by gavage to pregnant 
rats showed a NOAEL of 200 mg/kg bw/day of 2-ethylbutyric acid. This dose is more than 4 x 107 
times higher than the MSDI for 2-ethylbutyric acid arising from the intake of hex-3-enyl 2-
ethylbutyrate [FL-no: 09.884]. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach the flavouring substances in the 
present group evaluation would not give rise to safety concerns at the estimated levels of intake 
arising from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 15 to 69000 
µg/person/day for the 53 flavouring substances from structural class I for which data have been 
provided. For 40 substances the mTAMDI were above the threshold of concern of 1800 
µg/person/day. The estimated intakes of the two flavouring substances assigned to structural class II, 
based on the mTAMDI, are 1600 and 3900 µg/person/day, which is above the threshold of concern 
for structural class II of 540 µg/person/day. The 13 flavouring substances [FL-no: 02.229, 05.061, 
05.082, 05.137, 05.174, 05.203, 05.217, 05.218, 05.220, 05.226, 09.562, 09.937 and 09.939], which 
have mTAMDI intake estimates below the threshold of concern for structural class I, are also 
expected to be metabolised to innocuous products.  
Thus, for 42 flavouring substances considered in this opinion, the intakes, estimated on the basis of 
the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substance has been assigned. For one substance [FL-no: 09.674], no use levels were provided. 
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Therefore, for these 43 substances more reliable exposure data are required. On the basis of such 
additional data, these flavouring substances should be reconsidered along the steps of the Procedure. 
Subsequently, additional toxicity data might become necessary.  
In order to determine whether the conclusion for the flavouring substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
all 56 flavouring candidate substances.  
Based on the available data the Panel concluded that the 56 flavouring substances in the present FGE 
would present no safety concern at the estimated levels of intake based of the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999), as last amended by Commission Decision 2008/163/EC (EC, 
2009). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behavior in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000), which is broadly based on the 
opinion of the Scientific Committee on Food (SCF, 1999). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002). 
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 (EC, 2002) and to take into account additional 
information that has been made available since the previous opinion on this FGE. 
The Union list of flavourings and source materials is established in Commission Regulation (EC) No 
872/2012 (EC, 2012). 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000), prior to their authorisation and inclusion in the Union list 
(Regulation (EC) No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
In addition, the Commission has asked EFSA to reflect newly submitted information on specifications 
in the revisions of FGEs. 
Flavouring Group Evaluation 06, Revision 4  
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ASSESSMENT 
1. History of the Evaluation  
The first version of the Flavouring Group Evaluation 06 (FGE.06) dealt with 35 straight- and 
branched-chain unsaturated primary alcohols, aldehydes, carboxylic acids and esters. 
The first Revision of FGE.06 (FGE.06Rev1) included the assessment of 12 additional flavouring 
substances [FL-no: 02.125, 02.234, 05.082, 05.203, 05.217, 05.218, 05.220, 08.102, 09.928, 09.937, 
09.938 and 09.939]. For [FL-no: 02.125] acute toxicity data were provided. Additional information on 
specifications and isomerism on 19 substances [FL-no: 02.152, 02.170, 02.195, 02.222, 05.061, 
08.074, 09.377, 09.567, 09.569, 09.572, 09.575, 09.638, 09.640, 09.643, 09.672, 09.673, 09.831, 
09.884 and 09.885] was made available (EFFA, 2007b) since FGE.06 was published. 
The second Revision of FGE.06 (FGE.06Rev2) included the assessment of one additional flavouring 
substance [FL-no: 09.674]. No toxicity and/or metabolism data were provided for this substance. 
Furthermore, for 24 substances [FL-no: 02.152, 02.175, 02.222, 02.234, 05.061, 05.082, 05.143, 
05.203, 05.217, 05.218, 08.074, 08.102, 09.341, 09.377, 09.612, 09.640, 09.831, 09.871, 09.872, 
09.884, 09.885, 09.937, 09.938 and 09.939], information from Industry (EFFA, 2010) on 
stereoisomeric composition and missing specifications, received after publication of Revision 1, was 
included in Revision 2. 
The third Revision of FGE.06 (FGE.06Rev3) included the assessment of two additional flavouring 
substances [FL-no: 05.226 and 09.950]. No toxicity or metabolism data were provided for these 
substances. Furthermore, information from Industry (EFFA, 2011a) on missing specifications and 
stereoisomeric composition on [FL-no: 09.674], received after publication of Revision 2, was 
included in Revision 3. 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.06 7 October 2004 http://www.efsa.europa.eu/en/efsajournal/pub/108.htm 35 
FGE.06Rev1 7 February 2007 http://www.efsa.europa.eu/en/efsajournal/pub/616.htm 47 
FGE.06Rev2 30 September 2010 http://www.efsa.europa.eu/en/efsajournal/pub/1844.htm 48 
FGE.06Rev3 28 September 2011 50 http://www.efsa.europa.eu/en/efsajournal/doc/2397.pdf 
FGE.06Rev4 30 January 2013 http://www.efsa.europa.eu/en/efsajournal/pub/3091.htm  56 
 
The present Revision of FGE.06, FGE.06Rev4, includes the assessment of six additional flavouring 
substances [FL-no: 02.229, 05.137, 05.170, 05.188, 09.562 and 09.854]. 
Two of the new substances, neral [FL-no: 05.170] and trans-3,7-dimethylocta-2,6-dienal [FL-no: 
05.188] (geranial), are α,β-unsaturated aldehydes. Citral [FL-no: 05.020], which is evaluated by the 
JECFA, is a mixture of these two substances and evaluated by the Panel in FGE.202 (EFSA, 2009), 
where it was concluded that there would be no safety concern with respect to genotoxicity or 
carcinogenicity for citral. Subsequently was citral considered by the Panel in FGE.72, together with 
21 other aliphatic branched-chain saturated and unsaturated alcohols, aldehydes, acids and related 
esters evaluated by the JECFA in 2003 (JECFA, 2004a). Consequently are the 22 substances from 
FGE.72 included as supporting substances in this Revision 4 of FGE.06. 
No toxicity or metabolism data were provided for the six substances. A search in the open literature 
did not provide any further data on toxicity or metabolism for these substances. However, an 
extensive database exists for citral (a mixture of neral and geranial), nerol, geraniol, citronellol, 
citronellal and citronellic acid which has been reviewed by the JECFA (JECFA, 2004b). 
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EFSA Journal 2013;11(2):3091 9 
Furthermore, information from Industry on missing specifications for three substances [FL-no: 
05.226, 09.938 and 09.950] (EFFA, 2011d) and on stereoisomeric composition for 13 substances [FL-
no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 09.377, 09.854, 09.640, 09.831, 09.884 
and 09.885] (EFFA, 2013a; EFFA, 2013b), received after publication of the last revision, is included 
in the present Revision. 
2. Presentation of the Substances in Flavouring Group Evaluation 06, Revision 4 
2.1. Description 
The present Flavouring Group Evaluation 6 Revision 4, FGE.06Rev4, using the Procedure as referred 
to in the Commission Regulation (EC) No 1565/2000 (the Procedure – shown in schematic form in 
Annex I of this FGE), deals with 56 straight- and branched-chain aliphatic unsaturated primary 
alcohols, aldehydes, carboxylic acids and esters. These flavouring substances (candidate substances) 
belong to chemical groups 1, 3 and 4 of Annex I of Regulation (EC) No 1565/2000 (EC, 2000). 
The flavouring substances under consideration, with their chemical Register name, FLAVIS (FL-), 
Chemical Abstract Service (CAS-), Council of Europe (CoE-) and Flavor and Extract Manufacturers’ 
Association (FEMA-) numbers, structure and specifications, are listed in Table 5. This group of 
candidate flavouring substances includes 30 straight or branched-chain esters [FL-no: 09.341, 09.368, 
09.377, 09.562, 09.567, 09.569, 09.572, 09.575, 09.612, 09.638, 09.640, 09.643, 09.672, 09.673, 
09.674, 09.831, 09.838, 09.854, 09.855, 09.871, 09.872, 09.884, 09.885, 09.897, 09.898, 09.928, 
09.937, 09.938, 09.939 and 09.950], 11 straight or branched-chain alcohols [FL-no: 02.125, 02.138, 
02.152, 02.170, 02.175, 02.176, 02.195, 02.201, 02.222, 02.229 and 02.234], 12 straight or branched-
chain aldehydes [FL-no: 05.061, 05.082, 05.137, 05.143, 05.170, 05.174, 05.188, 05.203, 05.217, 
05.218, 05.220 and 05.226] and three straight or branched-chain carboxylic acids [FL-no: 08.074, 
08.100 and 08.102].  
The outcome of the safety evaluation is summarised in Table 6. 
The hydrolysis products of the candidate esters are listed in Table 7. 
The candidate substances are structurally related to flavouring substances (supporting substances) 
evaluated at the 49th, 51st or 61st meetings of the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA). The structurally related substances are 26 esters derived from branched-chain 
terpenoid alcohols and aliphatic acyclic linear and branched-chain carboxylic acids (JECFA, 1998a; 
JECFA, 1999b) and 66 linear and branched-chain aliphatic, unsaturated, alcohols, aldehydes, 
carboxylic acids and related esters (JECFA, 1999a; JECFA, 2000a; JECFA, 2004a; JECFA, 2004b), 
previously evaluated by the JECFA.  
The names and structures of the 92 supporting substances are listed in Table 8, together with their 
evaluation status (JECFA, 1998a; JECFA, 1999a; JECFA, 1999b; JECFA, 2000a; JECFA, 2004a; 
JECFA, 2004b).  
Additional substances evaluated by the JECFA and structurally related to the 92 supporting 
substances are also taken into consideration in FGE.06Rev4 regarding toxicity and metabolism 
studies. 
2.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. 
Their flavour may be different, they may have different chemical properties resulting in possible 
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variability in their absorption, distribution, metabolism, elimination and toxicity. Thus information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Ten flavouring substances possess a chiral centre [FL-no: 02.170, 02.175, 02.229, 05.143, 09.341, 
09.612, 09.854, 09.871, 09.872 and 09.938]. For all 10 substances the stereoisomeric composition has 
been specified. 
Due to the presence and the position of double bonds, 38 of the candidate substances can exist as 
geometrical isomers [FL-no: 02.152, 02.195, 02.222, 02.234, 05.061, 05.082, 05.137, 05.170, 05.188, 
05.203, 05.217, 05.218, 05.220, 05.226, 08.074, 08.102, 09.377, 09.562, 09.567, 09.569, 09.572, 
09.575, 09.638, 09.640, 09.643, 09.672, 09.673, 09.674, 09.831, 09.838, 09.854, 09.855, 09.884, 
09.885, 09.928, 09.937, 09.939 and 09.950]. For all 38 substances the stereoisomeric composition has 
been specified (see Table 5). 
2.3. Natural Occurrence in Food 
Forty-one of the candidate substances have been reported to occur naturally in meat, fruits, spices, 
herbs, mushrooms, liquorice, vegetables, beer, beverage, cheese and/or butter, essential oils, tea, wine, 
cocoa, malt and cereals (TNO, 2012). Quantitative data on the natural occurrence in food have been 
reported for 23 of the substances (Table 1). 
Table 1: Candidate substances reported to occur in nature (TNO, 2012) 
FL-no: Name: Quantitative data reported 
02.175 2-Methylbut-3-en-1-ol Up to 1.1 mg/kg in guava fruit 
02.176 3-Methylbut-3-en-1-ol 
0.001 mg/kg in roasted chicken, up to 12.4 mg/kg in acerola 
(Malpighia), 0.01 mg/kg in apple, up to 0.3 in honey, 0.01 
mg/kg in melon, up to 0.01 mg/kg in Passiflora species, up to 
0.04 in raspberry, blackberry and boysenberry, and up to 0.12 
mg/kg in wine 
02.222 3-Pentenol-1 0.05 mg/kg in cloudberry juice and up to 0.01 mg/kg in milk 
05.137 Dec-4(cis)-enal 0.009 mg/kg in clam and up to 0.00099 mg/kg in tomato 
05.170 Neral 
0.002 mg/kg in grape, up to 4 mg/kg in tea, up to 6 mg/kg in 
tomato, less than 0.005 mg/kg in raspberry, blackberry and 
boysenberry, 0.03 mg/kg in macadamia nut and up to 0.01 
mg/kg in acerola  
05.188 trans-3,7-Dimethylocta-2,6-dienal 
0.03 mg/kg in macadamia nut, up to 0.7 mg/kg in tea, up to 
0.24 mg/mg in tomato, up to 0.05 mg/kg in raspberry, 
blackberry and boysenberry and 0.002 mg/kg in grape   
05.203 9-Octadecenal 2 mg/kg in roasted chicken 
08.100 4-Methylpent-3-enoic acid 0.32 mg/kg in beer 
09.341 Citronellyl hexanoate Up to 0.1 mg/kg in Passiflora species 
09.569 Hex-3-enyl octanoate Up to 3 mg/kg in citrus fruits, 0.14 mg/kg in guava and up to 0.25 mg/kg in Passiflora species 
09.572 Hex-4-enyl acetate Up to 1.56 mg/kg in banana 
09.575 3-Hexenyl heptanoate 0.08 mg/kg in guava 
09.638 Methyl dec-4-enoate Up to 0.1 mg/kg in apple and 0.014 in pineapple 
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FL-no: Name: Quantitative data reported 
09.643 Methyl geranate Up to 0.01 mg/kg in Passiflora species 
09.672 Non-3-enyl acetate 0.006 mg/kg in melon 
09.673 Non-6-enyl acetate 0.02 mg/kg in melon 
09.831 Ethyl 3,7-dimethyl-2,6-octadienoate Up to 0.016 mg/l in beer 
09.854 cis-3-Hexenyl 2-methylbutanoate 0.1 mg/kg in tea, less than 0.01 mg/kg in guava and feyoa 
09.855 trans-3-Hexenyl hexanoate 
0.8 mg/kg in honey, up to 0.6 mg/kg in strawberry, up to 0.07 
mg/kg in Passiflora species and up to 0.01 mg/kg in guava and 
feyoa 
09.928 trans-3-Hexenyl acetate 
Up to 0.05 mg/kg in banana, up to 0.03 mg/kg in guava fruit, 
up to 0.01 mg/kg in passion fruit, 0.01 mg/kg in apple and up to 
0.005 mg/kg in mango 
09.937 Methyl (3Z)-hexenoate Up to 0.25 mg/kg in guava fruit 
09.939 Ethyl (3Z)-hexenoate Up to 0.15 mg/kg in passion fruit and up to 0.01 mg/kg in 
guava 
09.950 (Z)-5-Octenyl acetate 0.05 mg/kg in banana 
 
According to the Flavour Industry, four candidate substances, oct-6-enal [FL-no: 05.061], 5-decenal 
[FL-no: 05.217], 16-octadecenal [FL-no: 05.218] and nona-3,6-dienyl acetate [FL-no: 09.674] in the 
present group are of artificial origin and have not been reported to occur naturally in foods (EFFA, 
2002d; EFFA, 2004b; Flavour Industry, 2008). However, [FL-no: 05.217] has been reported by TNO 
(2012) to occur in coriander leaf in trace amount and is included in the above 41 substances (TNO, 
2012). 
According to TNO (2012), a further 12 candidate substances have not been reported to occur naturally 
in any food items (TNO, 2012): 
Table 2:  Candidate substances not reported to occur in nature (TNO, 2012) 
FL-no: Name: 
 02.229 (-)-3,7-Dimethyl-6-octen-1-ol 
02.234 3-Nonen-1-ol 
05.061 Oct-6-enal 
05.218 16-Octadecenal 
05.220 4Z-Dodecenal 
05.226 E-4-Undecenal 
08.074 Dec-3-enoic acid 
09.562 trans-3-Hexenyl formate 
09.674 Nona-3,6-dienyl acetate 
09.838 3-Hexenyl methyl carbonate 
09.871 Citronellyl decanoate 
09.872 Citronellyl dodecanoate 
09.884 Hex-3-enyl-2-ethylbutyrate 
09.885 Hex-3-enyl hexadecanoate 
09.938 6-Methyl-5-hepten-2-yl acetate 
 
3. Specifications 
Purity criteria for the candidate substances have been provided by the Flavour Industry (EFFA, 
2001b; EFFA, 2002b; EFFA, 2004b; EFFA, 2006a; EFFA, 2011a; EFFA, 2011b; EFFA, 2013a; 
Flavour Industry, 2004; Flavour Industry, 2008; Flavour Industry, 2009). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the purity criteria for all candidate substances are sufficient (see Section 2.2 and Table 5).  
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4. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were 
conducted in 1995 by the International Organization of the Flavour Industry, in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population5
In the present Flavouring Group Evaluation (FGE.06Rev4) the total annual volume of production of 
the candidate substances from use as flavouring substances in Europe has been reported to be 
 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
                                                     
5  EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available 
for the enlarged EU.  
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approximately 24000 kg (EFFA, 2001b; EFFA, 2002c; EFFA, 2004c; EFFA, 2006b; EFFA, 2008; 
EFFA, 2011b; Flavour Industry, 2004; Flavour Industry, 2009). For 87 supporting substances the total 
annual volume of production is approximately 69000 kg (JECFA, 1999b; JECFA, 2000a; JECFA, 
2004a). The annual volumes of production in Europe for five of the substances [FL-no: 02.110, 
08.059, 09.141, 09.646 and 09.927] were not reported. 
On the basis of the annual volume of production reported for the candidate substances, MSDI values 
for each of these flavourings have been estimated (Table 6).  
Ninety-nine % of the total annual volume of production for the candidate substances is accounted for 
by six flavourings, (-)-3,7-dimethyl-6-octen-1-ol [FL-no: 02.229], neral [FL-no: 05.170], trans-3,7-
dimethylocta-2,6-dienal (geranial) [FL-no: 05.188], trans-3-hexenyl formate [FL-no: 09.562] methyl 
(3Z)-hexenoate [FL-no: 09.937] and ethyl (3Z)-hexenoate [FL-no: 09.939] and about 90 % is made up 
by neral [FL-no: 05.170] and trans-3,7-dimethylocta-2,6-dienal (geranial) [FL-no: 05.188], the two 
components of citral [FL-no 05.020]. The estimated MSDI values of (-)-3,7-dimethyl-6-octen-1-ol, 
neral, trans-3,7-dimethylocta-2,6-dienal (geranial), trans-3-hexenyl formate, methyl (3Z)-hexenoate 
and ethyl (3Z)-hexenoate from use as flavouring substances are 69, 950, 1600, 16, 120 and 120 
µg/capita/day, respectively. For all the remaining candidate substances the estimated daily per capita 
intakes are below 2 µg (Table 6). 
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages 
per day. 
For the present evaluation of the candidate substances, information on food categories and normal and 
maximum use levels6,7,8
For the present calculation of mTAMDI, the reported normal use levels were used. In the case where 
different normal use levels were reported for different food categories the highest reported normal use 
level was used in the calculation. 
 were submitted by the Flavour Industry (EFFA, 2001b; EFFA, 2002a; EFFA, 
2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 2004; Flavour Industry, 2009). 
No information on use levels have been submitted for nona-3,6-dienyl acetate [FL-no: 09.674]. For 55 
candidate substances the use in flavoured food products divided into the food categories, outlined in 
Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000), is shown in Table 3.  
According to the Flavour Industry the normal use levels for the 55 candidate substances, for which 
Industry has provided data on food categories and normal and maximum use level, are in the range of 
0.001 - 950 mg/kg food, and the maximum use levels are in the range of 0.05 - 1000 mg/kg (EFFA, 
2001b; EFFA, 2002a; EFFA, 2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 
2004; Flavour Industry, 2009). 
The mTAMDI values for the 53 candidate substances from structural class I for which data have been 
provided (see Section 7) range from 15 to 69000 µg/person/day. For the remaining two candidate 
substances from structural class II the mTAMDI is 1600 and 3900 µg/person/day. 
                                                     
6  “Normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002e). 
7  The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004a). 
8  The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Annex II. 
Table 3:  Use of Candidate Substances in Various Food Categories for 55 Candidate Substances 
for which Data on Use have been provided 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All except [FL-no: 02.125, 05.226] 
02.0 Fats and oils and fat emulsions (type water-in-oil) All except [FL-no: 02.125, 02.229, 05.170, 
05.188, 05.220, 09.562, 09.854] 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 02.229, 09.562, 09.854] 
04.1 Processed fruits All except [FL-no: 02.125, 02.229, 05.170, 
05.188, 09.854] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & 
tubers, pulses and legumes) and nuts & seeds 
Only [FL-no: 05.226, 09.928, 09.937, 
09.938, 09.939, 09.950] 
05.0 Confectionery All  
06.0 Cereals and cereal products, incl. flours & starches from 
roots & tubers, pulses & legumes, excluding bakery 
All except [FL-no: 02.125, 02.229, 02.234, 
05.170, 05.188, 09.562, 09.854] 
07.0 Bakery wares All except [FL-no: 02.125] 
08.0 Meat and meat products, including poultry and game All except [FL-no: 02.125, 02.229, 05.220, 
09.562, 09.854, 09.950,] 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
All except [FL-no: 02.125, 02.229, 05.170, 
05.188, 05.220, 05.226, 09.562, 09.854, 
09.950] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey Only [FL-no: 09.950] 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 02.125, 02.229, 05.143, 
05.220, 09.562, 09.854] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 02.125, 02.229, 05.137; 
05.143, 05.170, 05.188, 05.220, 05.226, 
09.562, 09.854, 09.937, 09.938, 09.939, 
09.950] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic 
counterparts 
All except [FL-no: 09.562] 
15.0 Ready-to-eat savouries All except [FL-no: 02.125, 02.229, 05.170, 
05.188, 05.226, 09.562, 09.854] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - 
foods that could not be placed in categories 1 – 15 
All except [FL-no: 02.125, 02.229, 05.137, 
05.170, 05.188, 05.220, 05.226, 09.562, 
09.854, 09.950] 
 
5. Absorption, Distribution, Metabolism and Elimination 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
any of the candidate substances except indirectly for neral [FL-no: 05.170] and trans-3,7-
dimethylocta-2,6-dienal [FL-no: 05.188] (geranial) which are the constituents of citral. 
The aliphatic alcohols, aldehydes and carboxylic acids in the present flavouring group are all expected 
to be absorbed from the gastrointestinal tract. Aliphatic esters are expected to be hydrolysed in the gut 
to yield the corresponding alcohols and carboxylic acids prior to absorption, or in the liver following 
absorption. 
In general, short chain (< C8) linear and branched-chain aliphatic esters, alcohols, aldehydes and 
carboxylic acids are rapidly absorbed from the gastrointestinal tract. Long-chain carboxylic acids, 
such as linoleic acid and oleic acid, are readily absorbed from micelles in the jejunum, re-esterified 
with glycerol in chylomicrons and transported via the lymphatic system.  
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In vitro hydrolysis data from studies with esters structurally related to the candidate substances 
indicate that the esters included in this evaluation are hydrolysed to yield the corresponding alcohols 
and carboxylic acids in the gut prior to absorption or in the blood and liver following absorption.  
The candidate alcohols are oxidized to their corresponding carboxylic acids via aldehydes. The 
candidate aldehydes are oxidized to their corresponding carboxylic acids. In general, the carboxylic 
acids included in the present flavouring group or resulting from the hydrolysis of esters or oxidation 
of alcohols and aldehydes are expected to complete their metabolism in the fatty acid pathway or 
tricarboxylic acid cycle. 
Branched-chain carboxylic acids resulting from ester hydrolysis, alcohol or aldehyde oxidation may 
be metabolised via omega- and/or beta-oxidation to yield polar metabolites, which are excreted as 
such or as glucuronic acid conjugates, primarily in the urine. Based on studies with geraniol and 
citral, the two terpene alcohols (citronellol [FL-no: 02.011] and lavendulol [FL-no: 02.170]) resulting 
from the hydrolysis of four of the candidate esters [FL-no: 09.341, 09.871, 09.872 and 09.612] 
included in the present flavouring group as well as the candidate substances neral [FL-no: 05.170], 
trans-3,7-dimethylocta-2,6-dienal [FL-no: 05.188] (geranial), (-)-3,7-dimethyl-6-octen-1-ol [FL-no: 
02.229], and after hydrolysis, methyl geranate [FL-no: 09.643] and ethyl 3,7-dimethyl-2,6-
octadienoate [FL-no: 09.831] are expected to undergo omega-oxidation and excretion as such or after 
conjugation with glucuronic acid. 
The hydrolysis of the candidate substance hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] generates 2-
ethylbutyric acid [FL-no: 08.045], which is resistant to beta-oxidation and has shown teratogenic 
potential (see Section 9.3). Although 2-ethylbutyric acid can be further conjugated with glucuronic 
acid or undergo omega-oxidation (see Annex III) the candidate substance [FL-no: 09.884] cannot be 
anticipated to be metabolised to innocuous products. 
Terminal double bonds appear in eleven candidate substances [FL-no: 02.125, 02.138, 02.170, 
02.175, 02.176, 02.201, 05.143, 05.174, 09.612, 09.897 and 09.898]. Of these, six are alcohols [FL-
no: 02.125, 02.138, 02.170, 02.175, 02.176 and 02.201], two are aldehydes [FL-no: 05.143 and 
05.174] and three are esters [FL-no: 09.612, 09.897 and 09.898]. Although theoretically, these double 
bonds may be oxidised to give reactive epoxides, it is expected that for these candidate substances, 
the metabolism via this pathway is negligible. The terminal double bonds are all present in molecules 
that have alcohol- or aldehyde functions at the end distal from the double bond. The alcohol- and 
aldehyde functions are expected to be readily attacked by oxidation processes, ultimately yielding 
unsaturated carboxylic acids, and also hydrolysis of the esters would yield the unsaturated alcohols. 
Biochemical attack of these carboxylic acids via e.g. beta-oxidation or conjugation with glucuronic 
acid is expected to be much more efficient and rapid than microsomal oxidation. 
In summary, it is generally anticipated that the candidate esters will undergo hydrolysis in the 
gastrointestinal tract, blood and liver to yield their corresponding aliphatic alcohols and carboxylic 
acids. Alcohols and aldehydes are oxidised to the corresponding carboxylic acids. The carboxylic 
acids will proceed their metabolism in the fatty acid pathway, tricarboxylic acid cycle, or undergo 
further oxidation and excretion as such or after glucuronic acid conjugation. Except for one candidate 
substance, hex-3-enyl 2-ethylbutyrate [FL-no: 09.884], all the candidate substances can be anticipated 
to be metabolised to innocuous products. 
A more detailed discussion on hydrolysis of linear and branched-chain esters, metabolism of linear 
saturated/unsaturated primary alcohols, aldehydes and carboxylic acids and branched-chain 
unsaturated primary alcohols, aldehydes and carboxylic acids follows in the Annex III. 
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6. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 7. 
For the safety evaluation of the candidate substances the Procedure as outlined in Annex I was 
applied, based on the MSDI approach. The stepwise evaluations of the substances are summarised in 
Table 6. 
All candidate substances are classified according to the decision tree approach by Cramer et al. 
(Cramer et al., 1978) into structural class I, except for two substances [FL-no: 05.143 and 09.884], 
which are classified into structural class II. 
Step 1 
Step 2 requires consideration of the metabolism of the candidate substances.  
Step 2 
One substance, hex-3-enyl 2-ethylbutyrate [FL-no: 09.884], will be hydrolysed to give 2-ethylbutyric 
acid [FL-no: 08.045], which showed teratogenic potential in one mouse subcutaneous single-dose 
study, and is structurally related to valproic acid, which is a known teratogen (see Section 9.3). 
Although the hydrolysis product is expected to be metabolised e.g. via conjugation with glucuronic 
acid or omega oxidation, it cannot be excluded that adverse effects might be elicited, and therefore 
[FL-no: 09.884] proceeds via the B-side of the Procedure scheme (Annex I). 
The evaluation of the remaining 55 candidate substances proceeds via the A-side of the Procedure 
(Annex I) as they are expected to be metabolised into innocuous products. 
Fifty four of the candidate substances proceeding via the A-side have been assigned to structural class 
I and have estimated European daily per capita intakes (MSDI) ranging from 0.001 to 1600 µg (Table 
6). These intakes are below the threshold of concern of 1800 µg/person/day for structural class I. 
Step A3 
One candidate substance proceeding via the A-side, [FL-no: 05.143], has been assigned to structural 
class II and has an estimated European daily per capita intake (MSDI) of 0.12 µg (Table 6). This 
intake is below the threshold of concern of 540 µg/person/day for structural class II. 
For these 55 candidate substances the conditions of use do not result in an intake greater than the 
threshold of concern for the respective structural classes. 
Based on results of the safety evaluation sequence these 55 candidate substances proceeding via the 
A-side of the Procedure do not pose a safety concern when used as flavouring substances at estimated 
levels of intake, based on the MSDI approach. 
 
This step is only relevant for hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] for which the estimated 
European daily per capita intake (MSDI) is 0.58 µg, which is below the threshold of concern for its 
Step B3 
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structural class (i.e. 540 µg/person/day for class II). Accordingly, this candidate substance proceeds to 
step B4 of the Procedure. 
The teratogenic activity of 2-ethylbutyric acid, a hydrolysis product of hex-3-enyl 2-ethylbutyrate 
[FL-no: 09.884], has been described in a single-dose study after subcutaneous administration of 600 
mg/kg body weight (bw) of 2-ethylbutyric acid to pregnant mice. Further, it should be taken into 
account that 2-ethylbutyric acid is structurally related to valproic acid, which is a well-known 
teratogen. 
Step B4 
In a study in which 2-ethylbutyric acid was administered by gavage to pregnant rats once daily on 
gestation days 6 to 15, at dose levels of 0, 150, or 200 mg/kg bw/day, a NOAEL of 200 mg/kg bw/day 
for the teratogenic activity of 2-ethylbutyric acid could be derived.  
The estimated daily per capita intake (MSDI) of the candidate substance [FL-no: 09.884] is 0.58 µg 
corresponding to approximately 0.005 µg 2-ethylbutyric acid/kg bw/day at a body weight of 60 kg. 
This intake is more than 4 x 107 lower than the NOAEL (200 mg/kg bw/day) for teratogenicity. 
Based on the results of the safety evaluation sequence (Annex I), this candidate substance, hex-3-enyl 
2-ethylbutyrate [FL-no: 09.884], does not pose a safety concern, including for teratogenicity, at the 
estimated level of intake, based on the MSDI approach. 
7. Comparison of the Intake Estimations Based on the MSDI- and the mTAMDI Approach 
The estimated intakes for 53 of the candidate substances in structural class I based on the mTAMDI 
range from 15 to 69000 µg/person/day. For 13 of the substances [FL-no: 02.229, 05.061, 05.082, 
05.137, 05.174, 05.203, 05.217, 05.218, 05.220, 05.226, 09.562, 09.937 and 09.939] the mTAMDI is 
below the threshold of concern of 1800 µg/person/day. For 40 of the candidate substances from class 
I, the mTAMDI is above the threshold of concern. For one substance [FL-no: 09.674] no information 
on use levels have been provided. 
The estimated intakes of the two substances [FL-no: 05.143 and 09.884] assigned to structural class 
II, based on the mTAMDI, are 1600 and 3900 µg/person/day, respectively, which is above the 
threshold of concern for structural class II substances of 540 µg/person/day. 
Thus, for 43 candidate substances further information is required. This would include more reliable 
intake data and where required additional toxicity data 
For comparison of the MSDI and mTAMDI values, see Table 4. 
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Table 4:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.125 Undec-10-en-1-ol 0.37 2000 Class I 1800 
02.138 Dec-9-en-1-ol 0.15 3900 Class I 1800 
02.152 Hept-3-en-1-ol 0.012 3900 Class I 1800 
02.170 Lavandulol 0.012 3900 Class I 1800 
02.175 2-Methylbut-3-en-1-ol 1.4 3900 Class I 1800 
02.176 3-Methylbut-3-en-1-ol 0.13 3900 Class I 1800 
02.195 Octa-3,5-dien-1-ol 0.061 3900 Class I 1800 
02.201 Pent-4-en-1-ol 0.012 3900 Class I 1800 
02.222 3-Pentenol-1 0.5 3900 Class I 1800 
02.229 (-)-3,7-Dimethyl-6-octen-1-ol 69 1400 Class I 1800 
02.234 3-Nonen-1-ol 0.011 3900 Class I 1800 
05.061 Oct-6-enal 0.0012 1600 Class I 1800 
05.082 Dodeca-3,6-dienal 0.011 1600 Class I 1800 
05.137 Dec-4(cis)-enal 1.3 15 Class I 1800 
05.170 Neral 950 69000 Class I 1800 
05.174 Pent-4-enal 0.11 1600 Class I 1800 
05.188 trans-3,7-Dimethylocta-2,6-dienal 1600 69000 Class I 1800 
05.203 9-Octadecenal 0.0097 1600 Class I 1800 
05.217 5-Decenal 0.11 1600 Class I 1800 
05.218 16-Octadecenal 0.011 1600 Class I 1800 
05.220 4Z-Dodecenal 1.2 36 Class I 1800 
05.226 E-4-Undecenal 0.61 54 Class I 1800 
08.074 Dec-3-enoic acid 0.19 3200 Class I 1800 
08.100 4-Methylpent-3-enoic acid 1.8 3200 Class I 1800 
08.102 Non-3-enoic acid 0.011 3200 Class I 1800 
09.341 Citronellyl hexanoate 0.97 3900 Class I 1800 
09.368 Ethyl 4-methylpent-3-enoate 0.12 3900 Class I 1800 
09.377 Ethyl oct-3-enoate 0.35 3900 Class I 1800 
09.562 trans-3-Hexenyl formate 16 320 Class I 1800 
09.567 Hex-3-enyl decanoate 0.0024 3900 Class I 1800 
09.569 Hex-3-enyl octanoate 0.49 3900 Class I 1800 
09.572 Hex-4-enyl acetate 0.0012 3900 Class I 1800 
09.575 3-Hexenyl heptanoate 0.61 3900 Class I 1800 
09.612 Lavandulyl acetate 0.012 3900 Class I 1800 
09.638 Methyl dec-4-enoate 0.0012 3900 Class I 1800 
09.640 Methyl deca-4,8-dienoate 0.012 3900 Class I 1800 
09.643 Methyl geranate 0.95 3900 Class I 1800 
09.672 Non-3-enyl acetate 0.012 3900 Class I 1800 
09.673 Non-6-enyl acetate 0.12 3900 Class I 1800 
09.674 Nona-3,6-dienyl acetate 0.0024  Class I 1800 
09.831 Ethyl 3,7-dimethyl-2,6-octadienoate 0.61 3900 Class I 1800 
09.838 3-Hexenyl methyl carbonate 0.012 3900 Class I 1800 
09.854 cis-3-Hexenyl 2-methylbutanoate 1.2 6000 Class I 1800 
09.855 trans-3-Hexenyl hexanoate 0.21 3900 Class I 1800 
09.871 Citronellyl decanoate 0.12 3900 Class I 1800 
09.872 Citronellyl dodecanoate 0.061 3900 Class I 1800 
09.885 Hex-3-enyl hexadecanoate 0.049 3900 Class I 1800 
09.897 3-Methylbut-3-en-1-yl butyrate 0.012 3900 Class I 1800 
09.898 3-Methylbut-3-en-1-yl hexanoate 0.012 3900 Class I 1800 
09.928 trans-3-Hexenyl acetate 1.8 3900 Class I 1800 
09.937 Methyl (3Z)-hexenoate 120 800 Class I 1800 
09.938 6-Methyl-5-hepten-2-yl acetate 1.2 40000 Class I 1800 
09.939 Ethyl (3Z)-hexenoate 120 800 Class I 1800 
09.950 Z-5-Octenyl acetate 0.61 7900 Class I 1800 
05.143 2,5-Dimethyl-2-vinylhex-4-enal 0.12 1600 Class II 540 
09.884 Hex-3-enyl-2-ethylbutyrate 0.58 3900 Class II 540 
8. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
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pathways, the combined intake estimates presented here are only preliminary. Currently, the 
combined intake estimates are only based on MSDI exposure estimates, although it is recognised that 
this may lead to underestimation of exposure. After completion of all FGEs, this issue should be 
readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated 
by summing the MSDI for individual substances.  
On the basis of the reported annual volume of production in Europe (EFFA, 2001b; EFFA, 2002c; 
EFFA, 2004c; EFFA, 2006b; EFFA, 2008; EFFA, 2011b; Flavour Industry, 2004; Flavour Industry, 
2009), the combined estimated daily per capita intake as flavouring of the 54 candidate substances 
assigned to structural class I is approximately 2900 µg (corresponding to 48 µg/kg bw/day), which 
exceeds the threshold of concern for the structural class of 1800 µg/person/day. About 90 % of this 
estimated daily intake is made up by neral [FL-no: 05.170] plus trans-3,7-dimethylocta-2,6-dienal 
(geranial) [FL-no: 05.188], the two components of the supporting substance citral [FL-no: 05.020], 
and the combined intake is 1250 times lower than the NOAEL of 60 mg/kg bw/day for the supporting 
substance citral, obtained in a 2-year carcinogenicity study in mice. 
For the two candidate substances assigned to structural class II the combined estimated daily per 
capita intake is 0.7 µg, which does not exceed the threshold of concern for structural class II of 540 
µg/person/day. 
The candidate substance hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] can be hydrolysed to the 
potential teratogenic substance 2-ethylbutyric acid (and hex-3-en-1-ol). No other candidate substances 
but one supporting substance, geranyl 2-ethylbutyrate [FL-no: 09.515], can be hydrolysed to 2-
ethylbutyric acid (and geraniol). The estimated combined intake of these two substances corresponds 
to 0.5 µg 2-ethylbutyric acid/capita/day. This combined intake corresponds to 0.01 µg 2-ethylbutyric 
acid/kg bw/day, which is more than 2 x 107 lower than the NOAEL of 200 mg/kg bw/day for 
teratogenicity of 2-ethylbutyric acid in the rat (Narotsky et al., 1994). Therefore, it can be concluded 
that the combined intake of hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] and geranyl 2-ethylbutyrate 
[FL-no: 09.515] does not pose a safety concern with respect to teratogenicity when used as flavouring 
substances at their estimated level of intakes, based on the MSDI approach. 
The candidate substances are structurally related to 92 supporting substances evaluated by the JEFCA 
at its 49th, 51st and 61st meeting (JECFA, 1999b; JECFA, 2000a; JECFA, 2004a). The estimated 
combined intake (in Europe) is approximately 14300 µg/capita/day for 87 of the substances, all 
belonging to structural class I. The intake in Europe were not reported for five of the supporting 
substances [FL-no: 02.110, 08.059, 09.141, 09.646 and 09.927].  
The total combined intake of the candidate and supporting substances from structural class I is 17200 
µg/capita/day (corresponding to approximately 0.3 mg/kg bw/day), which is 200 times lower than the 
NOAEL of 60 mg/kg bw/day for the supporting substance citral, obtained in a 2-year carcinogenicity 
study in mice. Most of this combined intake of candidate and supporting substances would originate 
from intake of geraniol, nerol, citronellol, rhodinol and their esters together with geranial, neral and 
citral. The Panel noted that the JECFA has evaluated citral at several occasions together with geranyl, 
neryl, citronellyl and rhodinyl esters and has allocated a group ADI of 0 - 0.5 mg/kg bw/day, 
expressed as citral for citral, citronellol, geranyl acetate, linalool and linalyl acetate (JECFA, 2004a). 
The estimated total combined intake of the candidate and supporting substances would not exceed this 
group ADI. In conclusion, at the level of exposure resulting from the use as flavourings, all the 
candidate and supporting substances are expected to be efficiently metabolised and would not be 
expected to saturate the metabolic pathways. For these reasons and in the light of the toxicological 
data on supporting substances (Tables 9, 10, 11, 12 and 13), the total combined intake of these 
substances would not be expected to be of safety concern. 
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9. Toxicity 
9.1. Acute Toxicity 
Data are available for four of the candidate substances and 53 supporting and structurally related 
substances. A few of these flavouring substances have oral LD50 values in mice and rats between 600 
and 3000 mg/kg body weight (bw) but most have LD50 values higher than 3000 mg/kg bw, indicating 
low oral acute toxicity of the candidate substances in the present group. 
The acute toxicity data are summarised in Table 9. 
9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
No subacute, subchronic, chronic nor carcinogenicity studies are available on the candidate 
substances. However, several studies, including long-term toxicity and carcinogenicity studies are 
available on citral [FL-no: 05.020] which is a mixture of the candidate substances neral [FL-no: 
05.170] and trans-3,7-dimethylocta-2,6-dienal (geranial) [FL-no: 05.188].  
Fourteen supporting substances were tested for subacute/subchronic toxicity and/or chronic toxicity, 
see Table 10.  
Three mouse carcinogenicity studies were performed with oleic acid [FL-no: 08.013] or oleic 
acid/linoleic acid mixture [FL-no: 08.013 / 08.041] (El-Khatib and Cora, 1981; Szepsenwol and 
Boschetti, 1975; Szepsenwol, 1978) and carcinogenicity studies in mice and rats were performed with 
citral [FL-no: 05.020] and a citronellyl acetate/geranyl acetate mixture [FL-no: 09.012 / 09.011] 
(NTP, 1987; NTP, 2003).  
The Panel noted the data provided on oleic acid [FL-no: 08.013] as a supporting substance. The 
former EU Scientific Committee on Food allocated in 1991 an ADI “not specified” to fatty acids, 
including oleic acid (CEC, 1991). High intakes of fatty acids may stimulate tumour development in 
the gastro-intestinal tract due to promoter activity, which can be considered as a threshold event (Liu 
et al., 2001; Reddy, 1992; Reddy, 1995; Zhang et al., 1996). In addition, apart from aneuploidy 
(threshold genotoxic event), no other genotoxic effects with oleic acid were observed. The Panel 
concludes that the carcinogenicity of the oleic acid or linoleic acid/oleic acid mixture, if any, is not 
relevant with respect to assessment of the candidate substances in this group.  
Long-term toxicity and carcinogenicity studies have been performed with citral in mice and rats 
(NTP, 2003) and were previously evaluated by the Panel in FGE.202 (EFSA, 2009) as follows: 
“Groups of 50 male and 50 female F344/N rats were fed diets containing 0 (controls), 1000, 2000 or 
4000 mg microencapsulated citral per kg diet for two years, equivalent to 0, 50, 100 and 210 mg 
citral/kg body weight (bw) per day. Mean body weights of rats exposed to 4000 mg citral/kg diet were 
generally less than those of the controls in the last part of the study. Feed consumption by the exposed 
groups was similar to that by the controls. According to the authors, no neoplasms or non-neoplastic 
lesions were attributed to exposure to citral (NTP, 2003). 
Groups of 50 male and 50 female B6C3F1 mice were fed diets containing 0, 500, 1000 or 2000 mg 
microencapsulated citral for two years, equivalent to 0, 60, 120 and 260 mg citral/kg bw per day. 
Mean body weights of mice exposed to 1000 or 2000 mg citral/kg diet were generally less than those 
of the controls throughout the study, and mean body weights of the females receiving 500 mg/kg diet 
were slightly less (less than 10 %) from week 30 to the end of the study. Feed consumption by the 
exposed groups was similar to that by the controls. According to the authors, the incidences of 
malignant lymphomas occurred with a positive trend in female mice (6, 10, 18 and 24 %), and the 
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incidence in the high-dose group was significantly greater than that in the control group. However, all 
incidences were within the historical control range of 6 - 30 %. There were no increases in tumour 
incidences in male mice (NTP, 2003). 
Overall, the Panel concluded that citral was not carcinogenic in male mice and in rats. The higher 
incidence of malignant lymphomas observed in female mice was considered biologically non-
relevant”. Further, citral was not genotoxic in a set of in vitro and in vivo tests” (See Section 9.4). 
The Panel noted that the NOAEL for citral in rats was 100 mg/kg bw per day on the basis of 
decreased body weights (in particular in females), whereas on the basis of decreased body weights, 
the NOAEL for citral was 60 mg/kg bw per day in female mice and 120 mg/kg bw per day in male 
mice. 
A mixture of 29 % citronellyl acetate and 71 % geranyl acetate [FL-no: 09.012 / 09.011] was tested in 
rats and mice at dose levels of 0, 1000 and 2000 mg/kg bw/day (rats) or 0, 500 and 1000 mg/kg 
bw/day (mice) via gavage (NTP, 1987). These studies showed an increase of kidney tubular cell 
adenomas in low dose male rats, 2/50 (4 %), but 0/50 in controls and highest dose male rats. For skin 
squamous cell papillomas there was an increase 4/50 (8 %) in low dose male rats, but 0/50 in controls 
and 1/50 in highest dose male rats. The increased tumor incidence was observed in low dose male rats 
and not in mice and in female rats. The authors concluded that “under the conditions of these studies, 
geranyl acetate was not carcinogenic for F344/N rats or B6C3F1 mice of either sex; however, the 
reduced survival observed in high dose male rats, high dose male mice and high and low dose female 
mice lowered the sensitivities of these studies for detecting neoplastic responses in these groups. In 
male rats the marginal increases of squamous cell papillomas of the skin and tubular cell adenomas of 
the kidney may have been related to administration of geranyl acetate” (NTP, 1987). Further, geranyl 
acetate, the main component of the mixture tested, was not genotoxic in a set of in vitro and in vivo 
tests (see Section 9.4). There were no genotoxicity studies available on citronellyl acetate. 
The Panel concurs with the conclusions of the peer reviewed NTP study that geranyl acetate was not 
carcinogenic. In this study the NOAEL for the mixture was 1000 mg/kg bw per day, 5 days per week, 
corresponding to an estimated dose of 710 mg/kg bw per day of geranyl acetate and 290 mg/kg bw per 
day of citronellyl acetate. 
Repeated dose toxicity data are summarised in Table 10. 
9.3. Developmental / Reproductive Toxicity Studies 
No adequate developmental and reproductive toxicity studies are available for any candidate 
substances for the present flavouring group evaluation. 
One valid study on developmental toxicity of the supporting substance citral in rats revealed a 
NOAEL of 60 mg/kg bw/day (fetal growth retardation and a higher incidence of minor skeletal 
abnormalities at doses higher than 60 mg/kg bw/day) (Nogueira et al., 1995). 
Two studies on developmental toxicity are available on a hydrolysis product, 2-ethylbutyric acid, of 
the candidate substance hex-3-enyl 2-ethylbutyrate [FL-no: 09.884]. Nau and Loescher (1986) studied 
valproic acid and a number of metabolites of valproic acid, as well as other related substances 
including 2-ethylbutyric acid [FL-no: 08.045]. The substances were tested with regard to their 
teratogenicity in mouse following single subcutaneous injections of 600 mg/kg on day 8 of gestation. 
Valproic acid as well as 4-en-valproic acid and a number of substances structurally related to valproic 
acid induced neural tube defects with an incidence from 0 % in controls, up to 61 % of live fetuses 
from mice treated with valproic acid (2 % of live fetuses for 2-ethylbutyric acid) (Nau and Löscher, 
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1986). The study demonstrates that teratogenicity varies significantly within the group of valproic 
acid metabolites and structurally related substances. 
Narotsky and co-workers (1994) studied the developmental effects of 2-ethylbutyric acid (and other 
aliphatic acids), administered by gavage to pregnant rats (Narotsky et al., 1994). Groups of pregnant 
Sprague-Dawley rats were given 0, 150 or 200 mg/kg bw/day of 2-ethylbutyric acid, on gestation days 
6 to 15. No developmental effects could be demonstrated. 
Developmental/reproductive toxicity data are summarised in Table 11. 
9.4. Genotoxicity Studies 
Experimental data are available for one candidate substance, methyl-3-but-3-en-1-ol [FL-no: 02.176], 
which was not mutagenic in the Ames test.  
There are data from in vitro genotoxicity tests for 12 supporting substances [FL-no: 02.011, 02.012, 
02.029, 05.020, 05.021, 05.124, 05.074, 05.139, 08.013, 09.011, 09.076 and 09.646]. The most 
extensively tested substances were oleic acid (six studies), geranyl acetate (12 studies) and citral (15 
studies).  
Oleic acid [FL-no: 08.013] gave negative results when tested in in vitro tests for point mutations with 
both bacterial and mammalian cells as well as in a Rec assay. In the absence of exogenous metabolic 
activation, oleic acid induced chromosomal numerical abnormalities in Chinese hamster V79 cells, 
but no increase in sister-chromatid exchanges (SCE). The increase in chromosomal numerical 
abnormalities, although not dose-dependent, was observed at all concentration levels.  
Geranyl acetate [FL-no: 09.011] was not mutagenic when tested in the Ames test. Negative results 
were also obtained in a Rec assay; moreover, it did not induce unscheduled DNA synthesis (UDS) in 
rat hepatocytes or chromosomal aberration in Chinese hamster ovary (CHO) cells, where it was also 
not able to inhibit DNA synthesis. Geranyl acetate gave weakly positive results in the SCE assay in 
CHO cells, although only at cytotoxic concentrations. In two poorly reported studies, it appeared 
weakly mutagenic at the TK locus in the mouse lymphoma assay in the presence of exogenous 
metabolic activation. In contrast, negative results were obtained in a valid, well-reported study on 
gene mutation at a TK6 locus in human lymphoblasts. The genotoxic potential of geranyl acetate was 
also assessed in vivo: negative results were obtained in a micronucleus test in mice and in UDS 
induction in rats. Negative data on in vivo genotoxicity were also available for another supporting 
substance 2,6-dimethyl-5-heptanal [FL-no: 05.074]. 
Citral was previously evaluated for genotoxicity in FGE.202 (EFSA, 2009) as follows: “Citral [FL-no: 
05.020] was not mutagenic in several valid Ames tests (Gomes-Carneiro et al., 1998; Ishidate et al., 
1984; NTP, 2003; Zeiger et al., 1987) and it did not induce chromosome aberrations in a valid in vitro 
study with CHO cells (NTP, 2003). Moreover, it was negative in a valid in vivo mouse bone marrow 
micronucleus assay. The positive results in an in vitro test for sister chromatid exchanges (SCE) 
(NTP, 2003 ) and in inappropriate test systems like the Rec assay in B. subtilis (Yoo, 1986) and the 
induction of the tumour suppressor protein p53 (Duerksen-Hughes et al., 1999) are considered of 
limited relevance for the overall evaluation. The Panel concluded that for citral genotoxicity is not of 
concern.” 
All the remaining valid in vitro genotoxicity studies, performed with different supporting substances 
(geranyl formate [FL-no: 09.076], 2,6-dimethyl-5-heptenal [FL-no: 05.074], methyl linoleate & 
methyl linolenate (mixture) [FL-no: 09.646], 9-decenal [FL-no: 05.139], 3-methylcrotonaldehyde [FL-
no: 05.124], citronellal [FL-no: 05.021], 3,7,11-trimethyldodeca-2,6,10-trien-1-ol [FL-no: 02.029] 
(farnesol), geraniol [FL-no: 02.012], citronellol [FL-no: 02.011]) gave negative results. 
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In summary, the validity of the weak positive results from the gene mutation assay performed with 
geranyl acetate is questionable, and the positive results with citral in an in vitro test for sister 
chromatid exchanges (SCE) and in inappropriate test systems like the Rec assay in B. subtilis and the 
induction of the tumour suppressor protein p53 are considered of limited relevance for the overall 
evaluation, taking into account the negative results from other in vitro and in vivo assays. The 
reported induction of aneuploidy by oleic acid can be considered as a threshold event. All the 
remaining genotoxicity tests on supporting substances gave negative results. Data are available for 
one candidate substance, methyl-3-but-3-en-1-ol, which was not mutagenic in the Ames test. On this 
basis and on the results on supporting substances it can be concluded that genotoxicity is not of 
concern for the candidate substances in this FGE. 
Genotoxicity data are summarised in Table 12 and Table 13. 
CONCLUSIONS 
The present revision of FGE.06, FGE.06Rev4, includes the assessment of six additional flavouring 
substances, (-)-3,7-dimethyl-6-octen-1-ol [FL-no: 02.229], dec-4(cis)-enal [FL-no: 05.137], neral [FL-
no: 05.170], trans-3,7-dimethylocta-2,6-dienal (geranial) [FL-no: 05.188], trans-3-hexenyl formate 
[FL-no: 09.562] and cis-3-hexenyl 2-methylbutanoate [FL-no: 09.854]. 
So, FGE.06Rev4 deals in total with 56 straight- and branched-chain unsaturated primary alcohols, 
aldehydes, carboxylic acids or esters.  
Ten candidate substances possess a chiral centre [FL-no: 02.170, 02.175, 02.229, 05.143, 09.341, 
09.612, 09.854, 09.871, 09.872 and 09.938]. For all 10 substances the stereoisomeric composition has 
been specified. 
Thirty-eight candidate substances can exist as geometrical isomers [FL-no: 02.152, 02.195, 02.222, 
02.234, 05.061, 05.082, 05.137, 05.170, 05.188, 05.203, 05.217, 05.218, 05.220, 05.226, 08.074, 
08.102, 09.377, 09.562, 09.567, 09.569, 09.572, 09.575, 09.638, 09.640, 09.643, 09.672, 09.673, 
09.674, 09.831, 09.838, 09.854, 09.855, 09.884, 09.885, 09.928, 09.937, 09.939 and 09.950]. For all 
38 substances the stereoisomeric composition has been specified. 
Fifty-four candidate substances are classified into structural class I and two substances [FL-no: 
05.143 and 09.884] are classified into structural class II according to the decision tree approach 
presented by Cramer et al. 
Forty-one flavouring substances in the present group have been reported to occur naturally in a wide 
range of food items. 
According to the default MSDI approach, the 54 flavouring substances belonging to structural class I 
have intakes in Europe from 0.0012 to 1600 µg/capita/day, and for the two substances from structural 
class II the intakes are 0.12 and 0.58 µg/person/day. These values are below the respective thresholds 
of concern for structural class I and II of 1800 and 540 µg/person/day, respectively.  
On the basis of the reported annual production volumes in Europe (MSDI approach), the combined 
intake of the 54 candidate substances belonging to structural class I and of the two candidate 
substances belonging to structural class II would result in a total intake of approximately 2900 
µg/capita/day (corresponding to 48 µg/kg bw/day) and 0.7 µg/capita/day, respectively. While the 
value for structural class II is below the threshold of concern for class II substances of 540 
µg/person/day, the value for the structural class I is above the threshold of concern for class I 
substances of 1800 µg/person/day. The total combined estimated intake of 87 of the 92 supporting 
substances for which European annual production data are available and of the 54 candidate 
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substances from structural class I is approximately 17200 µg/capita/day (corresponding to 
approximately 0.3 mg/kg bw/day) which is 200 times lower than the NOAEL of 60 mg/kg bw/day for 
the supporting substance citral, obtained in a 2-year carcinogenicity study in mice. Most of the 
estimated combined intake of candidate and supporting substances would originate from intake of 
geraniol, nerol, citronellol, rhodinol and their esters together with geranial, neral and citral. The Panel 
noted that JECFA has evaluated citral at several occasions together with geranyl, neryl, citronellyl 
and rhodinyl esters and have allocated a group ADI of 0 - 0.5 mg/kg bw/day, expressed as citral for 
citral, citronellol, geranyl acetate, linalool and linalyl acetate (JECFA, 2004a). The estimated 
combined intake would not exceed this group ADI. The Panel concludes that at the level of exposure 
resulting from the use as flavourings, all the candidate and supporting substances are expected to be 
efficiently metabolised and would not be expected to saturate the metabolic pathways. For these 
reasons and in the light of toxicological data on supporting substances, the total combined intake of 
these substances would not be expected to be of safety concern. 
For the substances in this group the data available do not give rise to safety concern with respect to 
genotoxicity and carcinogenicity.  
Except for hex-3-enyl 2-ethylbutyrate [FL-no: 09.884], the candidate substances are expected to be 
metabolised to innocuous products at the estimated levels of use as flavouring substances. One of the 
hydrolysis products of [FL-no: 09.884], 2-ethylbutyric acid, showed teratogenic potential in one 
mouse subcutaneous single-dose study and is structurally related to valproic acid, which is a known 
teratogen. However, an additional study in which 2-ethylbutyric acid was given by gavage to pregnant 
rats showed a NOAEL of 200 mg/kg bw/day of 2-ethylbutyric acid. This dose is more than 4 x 107 
times higher than the MSDI for 2-ethylbutyric acid arising from the intake of the candidate substance 
hex-3-enyl 2-ethylbutyrate [FL-no: 09.884]. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach the candidate substances would not 
give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 15 to 69000 
µg/person/day for the 53 flavouring substances from structural class I for which data have been 
provided. For 40 of the substances the intakes were above the threshold of concern for structural class 
I of 1800 µg/person/day. The estimated intakes of the two flavouring substances assigned to structural 
class II, are 1600 and 3900 µg/person/day, which is above the threshold of concern for structural class 
II of 540 µg/person/day. The 13 substances [FL-no: 02.229, 05.061, 05.082, 05.137, 05.174, 05.203, 
05.217, 05.218, 05.220, 05.226, 09.562, 09.937 and 09.939] from structural class I, which have 
mTAMDI intake estimates below the threshold of concern, are also expected to be metabolised to 
innocuous products.  
Thus, for 42 flavouring substances considered in this opinion, the intakes, estimated on the basis of 
the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substance has been assigned. For one substance [FL-no: 09.674] no use levels were provided. 
Therefore, for 43 substances more reliable exposure data are required. On the basis of such additional 
data, these flavouring substances should be reconsidered along the steps of the Procedure. 
Subsequently, additional data might become necessary.  
In order to determine whether the conclusion for the candidate substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
all 56 flavouring candidate substances. 
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Based on the available data the Panel concluded that the 56 flavouring substances would present no 
safety concern at the estimated levels of intake based of the MSDI approach. 
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Table 5: Specification Summary of the Substances in the Flavouring Group Evaluation 06, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
02.125 
 
Undec-10-en-1-ol OH   
10319 
112-43-6 
Liquid 
C11H22O 
170.29 
Practically insoluble or 
insoluble 
Freely soluble 
245-248 
 
MS 
95 % 
1.445-1.451 
0.845-0.851 
 
 
02.138 
 
Dec-9-en-1-ol OH   
 
13019-22-2 
Liquid 
C10H20O 
156.27 
Practically insoluble or 
insoluble 
Freely soluble 
86 (3 hPa) 
 
MS 
95 % 
1.445-1.451 
0.842-0.848 
 
 
02.152 
 
Hept-3-en-1-ol OH
(E)-isomer shown  
 
10219 
10606-47-0 
Liquid 
C7H14O 
114.19 
Practically insoluble or 
insoluble 
Freely soluble 
80 (27 hPa) 
 
MS 
95 % 
1.439-1.445 
0.848-0.854 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 60-
90 % E-form and 10-40 % Z-
form (EFFA, 2013a). 
02.170 
 
Lavandulol 
OH
 
 
 
498-16-8 
Liquid 
C10H18O 
154.25 
Practically insoluble or 
insoluble 
Freely soluble 
78 (7 hPa) 
 
MS 
95 % 
1.467-1.473 
0.877-0.883 
 
Register name to be changed 
to (R)-(-)-Lavandulol (EFFA, 
2007b). 
02.175 
 
2-Methylbut-3-en-1-ol OH
 
 
10259 
4516-90-9 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
Freely soluble 
122 
 
MS 
95 % 
1.421-1.427 
0.841-0.847 
 
Racemate (EFFA, 2010). 
02.176 
 
3-Methylbut-3-en-1-ol OH
 
 
10260 
763-32-6 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
Freely soluble 
130 
 
MS 
95 % 
1.431-1.437 
0.850-0.856 
 
 
02.195 
 
Octa-3,5-dien-1-ol OH   
 
70664-96-9 
Liquid 
C8H14O 
126.20 
Practically insoluble or 
insoluble 
Freely soluble 
90 (24 hPa) 
 
NMR 
95 % 
1.457-1.463 
0.865-0.871 
 
Register name to be changed 
to Octa-(3Z,5E)-dien-1-ol 
(EFFA, 2007b). 
02.201 
 
Pent-4-en-1-ol OH   
 
821-09-0 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
Freely soluble 
137 
 
MS 
95 % 
1.427-1.433 
0.843-0.849 
 
 
02.222 
 
3-Pentenol-1 OH
(E)-isomer shown  
 
10298 
39161-19-8 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
Freely soluble 
134 
 
MS 
95 % 
1.432-1.438 
0.846-0.852 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 50-
70 % E-form and 30-50 % Z-
form (EFFA, 2013a). 
02.229 
 
(-)-3,7-Dimethyl-6-octen-1-ol 
OH  
2309 
 
Liquid 
C10H20O 
Soluble 
Soluble 
225 
 
1.454-1.462 
0.850-0.860 
 
At least 90 % cis-isomer; 
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Table 5: Specification Summary of the Substances in the Flavouring Group Evaluation 06, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
7540-51-4 156.27 MS 
90 % 
secondary components 2-6 
% di-unsaturated and 
saturated C10 alcohols, 2-4 
% citronellyl acetate and 2-3 
% citronellal (EFFA, 2011c). 
02.234 
 
3-Nonen-1-ol OH  4412 
10293 
10340-23-5 
Liquid 
C9H18O 
142.24 
Practically insoluble or 
insoluble 
Freely soluble 
115 (33 hPa) 
 
MS 
95 % 
1.452-1.458 
0.862-0.868 
Register name to be changed 
to (3Z)-Nonen-1-ol (EFFA, 
2010). 
 
05.061 
 
Oct-6-enal O
(E)- isomer shown  
 
664 
63826-25-5 
Liquid 
C8H14O 
126.20 
Practically insoluble or 
insoluble 
Freely soluble 
87 (67 hPa) 
 
NMR 
95 % 
1.433-1.439 
0.842-0.848 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 50-
70 % E-form and 30-50 % Z-
form (EFFA, 2013a). 
05.082 
 
Dodeca-3,6-dienal O   
2121 
13553-09-8 
Liquid 
C12H20O 
180.24 
Practically insoluble or 
insoluble 
Freely soluble 
226 
 
MS 
95 % 
1.440-1.446 
0.844-0.850 
Register name to be changed 
to Dodeca-(3Z,6Z)-dienal 
(EFFA, 2010). 
 
05.137 
 
Dec-4(cis)-enal O  3264 
2297 
21662-09-9 
Liquid 
C10H18O 
154.25 
Insoluble 
Soluble 
80 (1.3 hPa) 
 
MS 
90 % 
1.442-1.447 
0.843-0.850 
At least 90 %. Secondary 
component at least 5 % 
trans-isomer (EFFA, 2011c). 
05.143 
 
2,5-Dimethyl-2-vinylhex-4-enal O
 
 
 
56134-05-5 
Liquid 
C10H16O 
152.24 
Sparingly soluble 
Freely soluble 
72 (16 hPa) 
 
MS 
95 % 
1.452-1.458 
0.845-0.851 
Racemate (EFFA, 2010). 
05.170 
 
Neral 
O  
2303 
 
106-26-3 
Liquid 
C10H16O 
152.24 
Very slightly soluble 
Soluble 
228 
 
MS 
96 % 
1.486-1.490 
0.885-0.891 
Neral is the cis-isomer of 
3,7-Dimethylocta-2,6-dienal. 
Neral and geranial can only 
be distinghished based on 
GC properties (different 
Kovats retention index) 
(EFFA, 2012b). 
05.174 
 
Pent-4-enal O   
 
2100-17-6 
Liquid 
C5H8O 
84.12 
Slightly soluble 
Freely soluble 
103 
 
MS 
95 % 
1.413-1.420 
0.849-0.855 
 
 
05.188 
 
trans-3,7-Dimethylocta-2,6-dienal 
O  
2303 
 
141-27-5 
Liquid 
C10H16O 
152.24 
Slightly soluble 
Soluble 
228 
 
MS 
96 % 
1.486-1.490 
0.885-0.891 
Geranial is the trans-isomer 
of 3,7-Dimethylocta-2,6-
dienal. Neral and geranial 
can only be distinghished 
based on GC properties 
(different Kovats retention 
index) (EFFA, 2012b). 
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Table 5: Specification Summary of the Substances in the Flavouring Group Evaluation 06, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
05.203 
 
9-Octadecenal O
(E)-isomer shown  
 
 
5090-41-5 
Liquid 
C18H34O 
266.47 
Practically insoluble or 
insoluble 
Freely soluble 
168 (5 hPa) 
 
MS 
95 % 
1.455-1.461 
0.848-0.854 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 85-
88 % Z-form and 8-10 % E-
form and 3-5 % octadecanal 
(EFFA, 2013a). 
05.217 
 
5-Decenal O   
 
21662-08-8 
Liquid 
C10H18O 
154.25 
Practically insoluble or 
insoluble 
Freely soluble 
92 (3 hPa) 
 
MS 
95 % 
1.441-1.447 
0.842-0.848 
Register name to be changed 
to (5Z)-Decenal (EFFA, 
2010). 
 
05.218 
 
16-Octadecenal O
(E)-isomer shown  
 
 
56554-87-1 
Solid 
C18H34O 
266.46 
Practically insoluble or 
insoluble 
Freely soluble 
391 
56 
MS 
95 % 
n.a. 
n.a. 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 50-
70 % E-form and 30-50 % Z-
form (EFFA, 2013a). 
05.220 
 
4Z-Dodecenal O  4036 
 
21944-98-9 
Liquid 
C12H22O 
182.30 
Slightly soluble 
Very soluble 
254 
n.a. 
IR NMR MS 
94 % 
1.443-1.449 
0.843-0.849 
Known imputities: 1.06 % 
4E-dodecenal, 3.66 % 
dodecanal (FL-no: 05.011), 
1.29 % tetradecane (FL-no: 
01.057). 
05.226 
 
E-4-Undecenal O  4672 
 
68820-35-9 
Liquid 
C11H20O 
168.15 
Insoluble 
Soluble 
237.2 +/- 9.0 
 
IR 
> 95% 
1.4410-1.4511 
0.831-0.843 
(20°C) 
 
 
08.074 
 
Dec-3-enoic acid 
OH
O
E-isomer shown  
 
10088 
15469-77-9 
Liquid 
C10H18O2 
170.25 
Practically insoluble or 
insoluble 
Freely soluble 
158 
 
MS 
95 % 
1.437-1.457 
0.933-0.939 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 60-
90 % E-form and 10-40 % Z-
form (EFFA, 2013a). 
08.100 
 
4-Methylpent-3-enoic acid 
OH
O
 
 
 
504-85-8 
Liquid 
C6H10O2 
114.14 
Sparingly soluble 
Freely soluble 
99 (13 hPa) 
 
MS 
95 % 
1.443-1.449 
0.973-0.979 
 
 
08.102 
 
Non-3-enoic acid 
O
OH
(E)-isomer shown  
 
10154 
4124-88-3 
Liquid 
 
156.22 
Very slightly soluble 
Freely soluble 
158 (24 hPa) 
 
MS 
95 % 
1.445-1.451 
0.925-.0931 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 60-
90 % E-form and 10-40 % Z-
form (EFFA, 2013a). 
09.341 
 
Citronellyl hexanoate 
O
O
 
 
 
10580-25-3 
Liquid 
C16H30O2 
254.41 
Practically insoluble or 
insoluble 
Freely soluble 
240 
 
MS 
95 % 
1.446-1.450 
0.871-0.876 
Racemate (EFFA, 2010). 
09.368 
 
Ethyl 4-methylpent-3-enoate 
O
O
 
 
10615 
6849-18-9 
Liquid 
C8H14O2 
142.20 
Practically insoluble or 
insoluble 
Freely soluble 
66 (23 hPa) 
 
MS 
95 % 
1.427-1.433 
0.910-0.916 
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Table 5: Specification Summary of the Substances in the Flavouring Group Evaluation 06, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
09.377 
 
Ethyl oct-3-enoate 
O
O
(E)-isomer shown  
4361 
10618 
1117-65-3 
Liquid 
C10H18O2 
170.25 
Practically insoluble or 
insoluble 
Freely soluble 
94 (13 hPa) 
 
MS 
95 % 
1.431-1.439 
0.903-0.910 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 60-
90 % E-form and 10-40 % Z-
form (EFFA, 2013a). 
09.562 
 
trans-3-Hexenyl formate O O  3353 
 
56922-80-6 
Liquid 
C7H12O2 
128.17 
Insoluble 
Soluble 
156 
 
MS 
98 % 
1.421-1.431 
0.907-0.914 
 
 
09.567 
 
Hex-3-enyl decanoate 
O
O
 
 
 
85554-69-4 
Liquid 
C16H30O2 
254.41 
Practically insoluble or 
insoluble 
Freely soluble 
315 
 
MS 
95 % 
1.439-1.445 
0.875-0.881 
Register name to be changed 
to Hex-(3Z)-enyl decanoate 
(EFFA, 2007b). 
09.569 
 
Hex-3-enyl octanoate 
O
O
 
 
 
61444-41-5 
Liquid 
C14H26O2 
226.36 
Practically insoluble or 
insoluble 
Freely soluble 
286 
 
MS 
95 % 
1.431-1.451 
0.878-0.884 
Register name to be changed 
to Hex-(3Z)-enyl octanoate 
(EFFA, 2007b). 
09.572 
 
Hex-4-enyl acetate 
O
O
 
 
 
42125-17-7 
Liquid 
C8H14O2 
142.20 
Practically insoluble or 
insoluble 
Freely soluble 
73 (27 hPa) 
 
MS 
95 % 
1.426-1.432 
0.900-0.906 
Register name to be changed 
to Hex-(4Z)-enyl acetate 
(EFFA, 2007b). 
09.575 
 
3-Hexenyl heptanoate 
O
O
 
 
 
61444-39-1 
Liquid 
C13H24O2 
212.33 
Practically insoluble or 
insoluble 
Freely soluble 
270 
 
MS 
95 % 
1.433-1.439 
0.880-0.886 
Register name to be changed 
to Hex-(3Z)-enyl heptanoate 
(EFFA, 2007b). 
09.612 
 
Lavandulyl acetate 
O
O  
 
 
25905-14-0 
Liquid 
C12H20O2 
196.29 
Practically insoluble or 
insoluble 
Freely soluble 
100 (15 hPa) 
 
MS 
95 % 
1.453-1.459 
0.909-0.915 
Racemate (EFFA, 2010). 
09.638 
 
Methyl dec-4-enoate 
O
O
 
 
10784 
7367-83-1 
Liquid 
C11H20O2 
184.28 
Practically insoluble or 
insoluble 
Freely soluble 
112 (20 hPa) 
 
MS 
95 % 
1.438-1.444 
0.891-0.897 
Register name to be changed 
to Methyl dec-(4Z)-enoate 
(EFFA, 2007b). 
09.640 
 
Methyl deca-4,8-dienoate 
O
O
(4E, 8E)-isomer shown  
 
10782 
1191-03-3 
Liquid 
C11H18O2 
182.26 
Practically insoluble or 
insoluble 
Freely soluble 
241 
 
NMR 
95 % 
1.443-1.449 
0.904-0.910 
Mixture of 
(E,E)/(E,Z)/(Z,E)/(Z,Z) 
(EFFA, 2010), 30-40% 
(E,E), 20-30 % (E,Z)/(Z,E) 
and 10-20 % (Z,Z) (EFFA, 
2013a). 
09.643 
 
Methyl geranate O
O
 
 
10797 
1189-09-9 
Liquid 
C11H18O2 
182.26 
Insoluble 
Freely soluble 
97 (13 hPa) 
 
MS 
95 % 
1.465-1.471 
0.916-0.925 
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FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
09.672 
 
Non-3-enyl acetate 
O
O
 
 
 
13049-88-2 
Liquid 
C11H20O2 
184.28 
Practically insoluble or 
insoluble 
Freely soluble 
61 (0.1 hPa) 
 
MS 
95 % 
1.429-1.435 
0.886-0.892 
Register name to be changed 
to Non-(3Z)-enyl acetate 
(EFFA, 2007b). 
09.673 
 
Non-6-enyl acetate 
O
O
 
 
 
76238-22-7 
Liquid 
C11H20O2 
184.28 
Practically insoluble or 
insoluble 
Freely soluble 
90 (4 hPa) 
 
MS 
95 % 
1.432-1.438 
0.886-0.892 
Register name to be changed 
to Non-(6Z)-enyl acetate 
(EFFA, 2007b). 
09.674 
 
Nona-3,6-dienyl acetate 
O
O
 
 
 
76649-26-8 
Liquid 
C11H18O2 
182.26 
Insoluble 
Soluble 
75 (20hPa) 
 
MS 
95% 
1.448-1.454 
0.898-0.905 
(Z)- or (E)-isomer not 
specified by CASrn in 
Register. CASrn to be 
changed to 211323-05-6 
(correspond to JECFA-no 
1285) and name to (E, Z)-
3,6-Nonadien-1-ol, acetate 
(EFFA, 2011a).  
09.831 
 
Ethyl 3,7-dimethyl-2,6-octadienoate O
O
(E)-isomer shown
 
 
 
13058-12-3 
Liquid 
C12H20O2 
196.29 
Practically insoluble or 
insoluble 
Freely soluble 
114 (13 hPa) 
 
MS 
95 % 
1.463-1.469 
0.911-0.917 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 60-
90 % E-form and 10-40 % Z-
form (EFFA, 2013a). 
09.838 
 
3-Hexenyl methyl carbonate 
O O
O
 
 
 
67633-96-9 
Liquid 
C8H14O3 
158.19 
Slightly soluble 
Freely soluble 
78 (4 hPa) 
 
MS 
98 % 
1.426-1.430 
0.966-0.971 
Register name to be changed 
(3Z)-Hexenyl methyl 
carbonate (EFFA, 2002c). 
09.854 
 
cis-3-Hexenyl 2-methylbutanoate 
O
O
 
3497 
2345 
53398-85-9 
Liquid 
C11H20O2 
184.28 
Insoluble 
Soluble 
212 
 
MS 
98 % 
1.428-1.434 
0.876-0.880 
 
Racemate (EFFA, 2013b). 
09.855 
 
trans-3-Hexenyl hexanoate 
O
O
 
 
 
56922-82-8 
Liquid 
C12H22O2 
198.30 
Practically insoluble or 
insoluble 
Freely soluble 
253 
 
MS 
95 % 
1.428-1.434 
0.883-0.889 
 
 
09.871 
 
Citronellyl decanoate 
O
O
 
 
 
72934-06-6 
Liquid 
C20H38O2 
310.52 
Practically insoluble or 
insoluble 
Freely soluble 
202 (13 hPa) 
 
NMR 
95 % 
1.448-1.454 
0.869-0.875 
Racemate (EFFA, 2010). 
09.872 
 
Citronellyl dodecanoate 
O
O
 
 
 
72934-07-7 
Liquid 
C22H42O2 
338.57 
Practically insoluble or 
insoluble 
Freely soluble 
217 (13 hPa) 
 
NMR 
95 % 
1.450-1.456 
0.867-0.873 
Racemate (EFFA, 2010). 
Flavouring Group Evaluation 06, Revision 4  
 
EFSA Journal 2013;11(2):3091 31 
Table 5: Specification Summary of the Substances in the Flavouring Group Evaluation 06, Revision 4 
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Specification comments 
09.884 
 
Hex-3-enyl-2-ethylbutyrate 
O
O
(E)-isomer shown  
 
 
233666-04-1 
Liquid 
C12H22O2 
198.30 
Practically insoluble or 
insoluble 
Freely soluble 
243 
 
NMR 
95 % 
1.426-1.432 
0.881-0.887 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 60-
90 % E-form and 10-40 % Z-
form (EFFA, 2013a). 
09.885 
 
Hex-3-enyl hexadecanoate 
O
O
(E)-isomer shown  
 
 
233666-03-0 
Liquid 
C22H42O2 
338.57 
Practically insoluble or 
insoluble 
Freely soluble 
387 
 
NMR 
95 % 
1.454-1.460 
0.867-0.873 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010), 50-
70 % E-form and 30-50 % Z-
form (EFFA, 2013a). 
09.897 
 
3-Methylbut-3-en- 
1-yl butyrate 
O
O
 
 
 
54702-13-5 
Liquid 
C9H16O2 
156.22 
Practically insoluble or 
insoluble 
Freely soluble 
184 
 
MS 
95 % 
1.439-1.445 
0.886-0.892 
 
 
09.898 
 
3-Methylbut-3-en-1-yl hexanoate 
O
O
 
 
 
53655-22-4 
Liquid 
C11H20O2 
184.28 
Practically insoluble or 
insoluble 
Freely soluble 
223 
 
MS 
95 % 
1.453-1.458 
0.877-0.883 
 
 
09.928 
 
trans-3-Hexenyl acetate O
O  
4413 
 
3681-82-1 
Liquid 
C8H14O2 
142.20 
Practically insoluble or 
insoluble 
Freely soluble 
201 
 
MS 
97 % 
1.420-1.426 
0.893-0.899 
 
 
09.937 
 
Methyl (3Z)-hexenoate 
O
O
 
 
 
13894-62-7 
Liquid 
C7H12O2 
128.17 
Sparingly soluble 
Soluble 
85 (107 hPa) 
 
MS 
> 95 % 
1.422-1.430 
0.914-0.924 
 
 
09.938 
 
6-Methyl-5-hepten-2-yl acetate O
O  
4177 
 
19162-00-6 
Liquid 
C10H18O2 
170.25 
Insoluble 
Soluble 
184 
 
MS 
> 97 % 
1.420-1.429 
0.893-0.903 
Racemate (EFFA, 2010). 
09.939 
 
Ethyl (3Z)-hexenoate 
O
O
 
4112 
 
64187-83-3 
Liquid 
C8H14O2 
142.20 
Sparingly soluble 
Soluble 
90 (67 hPa) 
 
MS 
> 96 % 
1.420-1.429 
0.893-0.903 
 
 
09.950 
 
Z-5-Octenyl acetate 
O
O
 
4671 
 
71978-00-2 
Liquid 
C10H18O2 
170.13 
Insoluble 
Soluble 
226.2 +/- 19.0 
 
IR 
> 95% 
1.4301-1.4401 
0.886-0.898 
(20°C) 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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Table 6:  Summary of Safety Evaluation Applying the Procedure (Based on Intakes Calculated by the MSDI Approach) 
Table 6: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(µg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the material of 
commerce [6), 7), or 8)] 
 
02.125 
 
Undec-10-en-1-ol OH  0.37 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.138 
 
Dec-9-en-1-ol OH  0.15 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.152 
 
Hept-3-en-1-ol OH
(E)-isomer shown  
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.170 
 
Lavandulol 
OH
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.175 
 
2-Methylbut-3-en-1-ol OH
 
1.4 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.176 
 
3-Methylbut-3-en-1-ol OH
 
0.13 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.195 
 
Octa-3,5-dien-1-ol OH  0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.201 
 
Pent-4-en-1-ol OH  0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.222 
 
3-Pentenol-1 OH
(E)-isomer shown  
0.5 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.229 
 
(-)-3,7-Dimethyl-6-octen-1-ol 
OH  
69 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.234 
 
3-Nonen-1-ol OH  0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.061 
 
Oct-6-enal O
(E)- isomer shown  
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.082 
 
Dodeca-3,6-dienal O  0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.137 
 
Dec-4(cis)-enal O  1.3 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.170 
 
Neral 
O  
950 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.174 
 
Pent-4-enal O  0.11 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.188 
 
trans-3,7-Dimethylocta-2,6-dienal 
O  
1600 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.203 
 
9-Octadecenal O
(E)-isomer shown  
0.0097 
 
Class I 
A3: Intake below threshold 
4) 6)  
Flavouring Group Evaluation 06, Revision 4  
 
EFSA Journal 2013;11(2):3091 33 
Table 6: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(µg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the material of 
commerce [6), 7), or 8)] 
 
05.217 
 
5-Decenal O  0.11 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.218 
 
16-Octadecenal O
(E)-isomer shown  
0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.220 
 
4Z-Dodecenal O  1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.226 
 
E-4-Undecenal O  0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.074 
 
Dec-3-enoic acid 
OH
O
E-isomer shown  
0.19 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.100 
 
4-Methylpent-3-enoic acid 
OH
O
 
1.8 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.102 
 
Non-3-enoic acid 
O
OH
(E)-isomer shown  
0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.341 
 
Citronellyl hexanoate 
O
O
 
0.97 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.368 
 
Ethyl 4-methylpent-3-enoate 
O
O
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.377 
 
Ethyl oct-3-enoate 
O
O
(E)-isomer shown  
0.35 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.562 
 
trans-3-Hexenyl formate O O  16 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.567 
 
Hex-3-enyl decanoate 
O
O
 
0.0024 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.569 
 
Hex-3-enyl octanoate 
O
O
 
0.49 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.572 
 
Hex-4-enyl acetate 
O
O
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.575 
 
3-Hexenyl heptanoate 
O
O
 
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.612 
 
Lavandulyl acetate 
O
O  
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 6: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(µg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the material of 
commerce [6), 7), or 8)] 
 
09.638 
 
Methyl dec-4-enoate 
O
O
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.640 
 
Methyl deca-4,8-dienoate 
O
O
(4E, 8E)-isomer shown  
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.643 
 
Methyl geranate O
O
 
0.95 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.672 
 
Non-3-enyl acetate 
O
O
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.673 
 
Non-6-enyl acetate 
O
O
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.674 
 
Nona-3,6-dienyl acetate 
O
O
 
0.0024 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.831 
 
Ethyl 3,7-dimethyl-2,6-
octadienoate 
O
O
(E)-isomer shown
 
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.838 
 
3-Hexenyl methyl carbonate 
O O
O
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.854 
 
cis-3-Hexenyl 2-methylbutanoate 
O
O
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.855 
 
trans-3-Hexenyl hexanoate 
O
O
 
0.21 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.871 
 
Citronellyl decanoate 
O
O
 
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.872 
 
Citronellyl dodecanoate 
O
O
 
0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.885 
 
Hex-3-enyl hexadecanoate 
O
O
(E)-isomer shown  
0.049 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.897 
 
3-Methylbut-3-en-1-yl butyrate 
O
O
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.898 
 
3-Methylbut-3-en-1-yl hexanoate 
O
O
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 6: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(µg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the material of 
commerce [6), 7), or 8)] 
 
09.928 
 
trans-3-Hexenyl acetate O
O  
1.8 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.937 
 
Methyl (3Z)-hexenoate 
O
O
 
120 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.938 
 
6-Methyl-5-hepten-2-yl acetate O
O  
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.939 
 
Ethyl (3Z)-hexenoate 
O
O
 
120 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.950 
 
Z-5-Octenyl acetate 
O
O
 
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.143 
 
2,5-Dimethyl-2-vinylhex-4-enal O
 
0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
09.884 
 
Hex-3-enyl-2-ethylbutyrate 
O
O
(E)-isomer shown  
0.58 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 5 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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Table 7: Evaluation Status of Hydrolysis Products of Candidate Esters  
Table 7: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 Methanol 
CH4O 
32.04 
H
H
H
OH
 
Not evaluated as flavouring substance  Not in EU-Register. 
 Hex-3(trans)-en-1-ol OH  Not evaluated as flavouring substance 
No safety concern e) 
 
 
 
Not in EU-Register (former [FL-no: 
02.158] JECFA no 1621. 
 3,6 Nonadienol HO  Not evaluated as flavouring substance  Not in EU-Register. 
 Hex-(3Z)-enoic acid 
OHO  
Not evaluated as flavouring substance  Not in EU-Register. 
 Oct-3-enoic acid 
OH
O
 
Not evaluated as flavouring substance  
 
 
Not in EU-Register (former [FL-no: 
08.105]. 
 Deca-4,8-dienoic acid O
HO  
Not evaluated as flavouring substance  Not in EU-Register. 
02.011 Citronellol 
1219 OH  
 
No safety concern a) 
Category A b) 
Class I 
A3: Intake below threshold 
 
02.056 Hex-3(cis)-en-1-ol 
315 
OH  Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Not endogenous,  
A5: Adequate NOAEL exists 
 
02.074 Hex-4-en-1-ol 
318 
OH
(E)-isomer shown  
Category 2 c) 
No safety concern d) 
Category B b) 
Class I 
A3: Intake below threshold 
 
02.078 Ethanol 
41 
OH  Category 1 c) 
No safety concern e) 
 
 
No evaluation 
At the forty-sixth JECFA meeting 
(JECFA, 1997a), the Committee 
concluded that ethanol posed no 
safety concern at its current level of 
intake when ethyl esters are used as 
flavouring agents. 
02.093 Non-6-en-1-ol 
324 
OH   
No safety concern d) 
 
 
Class I 
A3: Intake below threshold 
 
02.113 Oct-5(cis)-en-1-ol 
322 
OH  Category 2 c) 
No safety concern d) 
 
 
Class I 
A3: Intake below threshold 
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Table 7: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
02.124 6-Methylhept-5-en-2-ol 
 
OH
 
Category 2 c) 
 
 
FGE.07 
Class I 
A3: Intake below threshold 
 
02.159 Hex-3-en-1-ol 
315 
OH   
 
Category A b) 
 
 
No evaluation 
 
02.170 Lavandulol 
 
OH
 
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
02.176 3-Methylbut-3-en-1-ol 
 
OH
 
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
02.234 3-Nonen-1-ol 
 
OH   
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
08.001 Formic acid 
79 
OHO  Category 1 c) 
No safety concern f) 
Deleted b) 
 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
O
OH  
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.005 Butyric acid 
87 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.009 Hexanoic acid 
93 
O
OH  
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.010 Octanoic acid 
99 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.011 Decanoic acid 
105 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
Flavouring Group Evaluation 06, Revision 4  
 
EFSA Journal 2013;11(2):3091 38 
Table 7: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
08.012 Dodecanoic acid 
111 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.014 Hexadecanoic acid 
115 
OH
O
 
Category 1 c) 
No safety concern f) 
Deleted b) 
 
Class I 
A3: Intake below threshold 
 
08.028 Heptanoic acid 
96 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.045 2-Ethylbutyric acid 
257 
OH
O
 
Category 1 c) 
No safety concern f) 
Category B b) 
 
Class II 
A3: Intake below threshold 
 
08.046 2-Methylbutyric acid 
255 
O
OH
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.075 Dec-4-enoic acid 
1287 
OH
O
(E)-isomer shown  
 
No safety concern a) 
 
 
Class I 
A3: Intake below threshold 
 
08.081 Geranic acid 
1825 
OH
O
 
 
 
 
 
Class I 
A3: Intake below threshold 
 
08.100 4-Methylpent-3-enoic acid 
 
OH
O
 
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2004a). 
b) (CoE, 1992). 
c) (SCF, 1995). 
d) (JECFA, 2000a). 
e) (JECFA, 1997a). 
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f) (JECFA, 1999b). 
e)   (JECFA, 2007c). 
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Table 8: Supporting Substances Summary 
Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.011 Citronellol 
OH  
2309 
59 
106-22-9 
1219 
JECFA specification (JECFA, 
2003). 
320  
No safety concern a) 
Category A b) 
GrADI: 0-0.5 (JECFA, 2004a). 
02.012 Geraniol 
OH  
2507 
60 
106-24-1 
1223 
JECFA specification (JECFA, 
2003). 
550  
No safety concern a) 
Category A b) 
GrADI: 0-0.5 (JECFA, 1980). 
02.027 Rhodinol 
HO  
2980 
76 
6812-78-8 
1222 
JECFA specification (JECFA, 
2003). 
13  
No safety concern a) 
Deleted b) 
 
02.029 3,7,11-Trimethyldodeca-
2,6,10-trien-1-ol OH  
2478 
78 
4602-84-0 
1230 
JECFA specification (JECFA, 
2003). 
7.7  
No safety concern a) 
Category B b) 
 
02.056 Hex-3(cis)-en-1-ol OH  2563 
750c 
928-96-1 
315 
JECFA specification (JECFA, 
1998b) 
3700 Category 1 c) 
No safety concern d) 
Category A b) 
 
02.058 Nerol 
OH  
2770 
2018 
106-25-2 
1224 
JECFA specification (JECFA, 
2003). 
250  
No safety concern a) 
Category B b) 
 
02.074 Hex-4-en-1-ol OH
(E)-isomer shown  
3430 
2295 
6126-50-7 
318 
JECFA specification (JECFA, 
1998b) 
2.4 Category 2 c) 
No safety concern d) 
Category B b) 
JECFA evaluated 4-hexen-1-ol 
(CASrn as in Register). (Z)- or 
(E)-isomer not specified by 
CASrn in Register. 
02.076 2-Methylbutan-1-ol OH
 
3998 
2346 
137-32-6 
1199 
JECFA specification (JECFA, 
2003). 
0.73 Category 1 c) 
No safety concern a) 
Category B b) 
 
02.093 Non-6-en-1-ol OH  3465 
10294 
35854-86-5 
324 
JECFA specification (JECFA, 
2000b) 
2.2  
No safety concern d) 
 
JECFA evaluated cis-6-nonen-1-
ol (CASrn as in Register). CASrn 
in Register refers to (Z)-isomer. 
Register name to be changed to 
Non-6Z-en-1-ol. 
02.094 Oct-3-en-1-ol OH  3467 
10296 
20125-84-2 
321 
JECFA specification (JECFA, 
1998b) 
4.7 Category 2 c) 
No safety concern d) 
 
JECFA evaluated cis-3-octen-1-
ol (CASrn as in Register). CASrn 
in Register refers to the (Z)-
isomer. Register name to be 
changed to Oct-3Z-en-1-ol. 
02.109 3-Methylbut-2-en-1-ol 
OH  
3647 
11795 
556-82-1 
1200 
JECFA specification (JECFA, 
2003). 
4.6  
No safety concern a) 
 
 
02.110 2,6-Dimethylhept-6-en-1-ol 
OH
 
3663 
 
36806-46-9 
348 
JECFA specification (JECFA, 
2003) 
ND Category 3 c) 
No safety concern d) 
 
JECFA evaluated 2,6-dimethyl-6-
hepten-1-ol (CASrn as in 
Register). (R)- or (S)-enantiomer 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
not specified by CASrn in 
Register. 
02.113 Oct-5(cis)-en-1-ol OH  3722 
 
64275-73-6 
322 
JECFA specification (JECFA, 
2003) 
0.4 Category 2 c) 
No safety concern d) 
 
 
05.020 Citral 
O
(E)-isomer shown  
2303 
109 
5392-40-5 
1225 
JECFA specification (JECFA, 
2003). 
5844  
No safety concern a) 
Category A b) 
GrADI: 0-0.5 (JECFA, 2004a). 
05.021 Citronellal 
O  
2307 
110 
106-23-0 
1220 
JECFA specification (JECFA, 
2003). 
810  
No safety concern a) 
Category A b) 
 
05.035 Undec-10-enal O  3095 
122 
112-45-8 
330 
JECFA specification (JECFA, 
2001) 
0.32  
No safety concern d) 
Category B b) 
 
05.036 Undec-9-enal O
(E)-isomer shown  
3094 
123 
143-14-6 
329 
JECFA specification (JECFA, 
2003) 
0.97  
No safety concern d) 
Category A b) 
JECFA evaluated 9-undecenal 
(CASrn as in Register). (Z)- or 
(E)-isomer not specified by 
CASrn in Register. 
05.059 Non-6(cis)-enal O  3580 
661 
2277-19-2 
325 
JECFA specification (JECFA, 
2003) 
1.7  
No safety concern d) 
Category B b) 
 
05.074 2,6-Dimethylhept-5-enal 
O
 
2389 
2006 
106-72-9 
349 
JECFA specification (JECFA, 
2003) 
27 Category 1 c) 
No safety concern d) 
Category B b) 
JECFA evaluated 2,6-dimethyl-5-
heptenal (CASrn as in Register). 
(R)- or (S)-enantiomer not 
specified by CASrn in Register. 
05.075 Hex-3(cis)-enal O  2561 
2008 
6789-80-6 
316 
JECFA specification (JECFA, 
2000b) 
4.1  
No safety concern d) 
Category B b) 
 
05.085 Hept-4-enal O
(Z)-isomer shown  
3289 
2124 
6728-31-0 
320 
JECFA specification (JECFA, 
2000b) 
1.6  
No safety concern d) 
Category B b) 
JECFA evaluated 4-heptenal 
(CASrn as in Register). CASrn in 
Register refers to the (Z)-isomer.  
05.096 4-Decenal Ο
(E)-isomer shown  
3264 
2297 
30390-50-2 
326 
JECFA specification (JECFA, 
2001) 
0.97  
No safety concern d) 
Category B b) 
JECFA evaluated 4-decenal 
(CASrn as in Register). (Z)- or 
(E)-isomer not specified by 
CASrn in Register. 
05.113 Hex-4-enal O  3496 
10337 
4634-89-3 
319 
JECFA specification (JECFA, 
2000b) 
0.024  
No safety concern d) 
 
JECFA evaluated cis-4-hexenal 
(CASrn as in Register). CASrn in 
Register refers to the (Z)-isomer. 
Register name to be changed to 
Hex-4Z-enal. 
05.124 3-Methylcrotonaldehyde 
O  
3646 
10354 
107-86-8 
1202 
JECFA specification (JECFA, 
2003). 
3.3  
No safety concern a) 
 
 
05.128 Oct-5(cis)-enal O  3749 
 
41547-22-2 
323 
JECFA specification (JECFA, 
2003) 
0.0012  
No safety concern d) 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
05.148 Farnesal 
(Z,Z)-isomer shown
O  
4019 
 
19317-11-4 
1228 
JECFA specification (JECFA, 
2003) 
0.49  
No safety concern a) 
 
 
05.169 12-Methyltridecanal O
 
4005 
 
75853-49-5 
1229 
JECFA specification (JECFA, 
2003). 
0.24  
No safety concern a) 
 
 
08.013 Oleic acid 
OH
O
 
2815 
13 
112-80-1 
333 
JECFA specification (JECFA, 
2000b) 
830 Category 1 c) 
No safety concern d) 
Deleted b) 
 
08.036 Citronellic acid O
OH  
3142 
616 
502-47-6 
1221 
JECFA specification (JECFA, 
2003). 
2.7 Category 1 c) 
No safety concern a) 
Category A b) 
 
08.039 Undec-10-enoic acid 
OH
O
 
3247 
689 
112-38-9 
331 
JECFA specification (JECFA, 
1998b) 
26 Category 1 c) 
No safety concern d) 
Category A b) 
 
08.041 Octadeca-9,12-dienoic acid 
OH
O
 
3380 
694 
60-33-3 
332 
JECFA specification (JECFA, 
2003) 
110 Category 1 c) 
No safety concern d) 
Deleted b) 
Register name to be changed to 
Linoleic acid. 
08.044 2,4-Dimethylpent-2-enoic acid 
OH
O
 
3143 
744 
21016-46-6 
1211 
JECFA specification (JECFA, 
2003). 
0.12  
No safety concern a) 
Category B b) 
JECFA CASrn 66634-97-7 - (R)- 
or (S)-enantiomer not specified. 
CASrn in Register refers to (E)-
isomer. 
08.047 2-Methylheptanoic acid 
OH
O
 
2706 
2003 
1188-02-9 
1212 
JECFA specification (JECFA, 
2003). 
14 Category 1 c) 
No safety concern a) 
Category A b) 
 
08.048 Pent-4-enoic acid 
OH
O
 
2843 
2004 
591-80-0 
314 
JECFA specification (JECFA, 
1998b) 
3.9  
No safety concern d) 
Category B b) 
 
08.050 Hex-3-enoic acid 
OH
O
(E)-isomer shown  
3170 
2256 
4219-24-3 
317 
JECFA specification (JECFA, 
2000b) 
9.4 Category 1 c) 
No safety concern d) 
Category B b) 
JECFA evaluated 3-hexenoic acid 
(CASrn as in Register). (Z)- or 
(E)-isomer not specified by 
CASrn in Register. 
08.055 2-Methyl-2-pentenoic acid 
OH
O
 
3195 
11680 
3142-72-1 
1210 
JECFA specification (JECFA, 
2003). 
36  
No safety concern a) 
 
 
08.058 2-Methylpent-3-enoic acid 
OH
O
(E)-isomer shown  
3464 
10147 
37674-63-8 
347 
JECFA specification (JECFA, 
2001) 
1.2 Category 1 c) 
No safety concern d) 
 
JECFA evaluated 2-methyl-3-
pentenoic-acid (CASrn as in 
Register). (Z)- or (E)-isomer not 
specified by CASrn in Register. 
08.059 2-Methylpent-4-enoic acid 
OH
O
 
3511 
10148 
1575-74-2 
355 
JECFA specification (JECFA, 
1998b) 
ND Category N c) 
No safety concern d) 
 
JECFA evaluated 2-methyl-4-
pentenoic-acid (CASrn as in 
Register). (R)- or (S)-enantiomer 
not specified by CASrn in 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
Register. 
08.064 2-Methylcrotonic acid 
OH
O
 
3599 
10168 
80-59-1 
1205 
JECFA specification (JECFA, 
2003). 
4.1  
No safety concern a) 
 
 
08.065 Dec-9-enoic acid 
OH
O
 
3660 
10090 
14436-32-9 
328 
JECFA specification (JECFA, 
2001) 
0.097 Category 1 c) 
No safety concern d) 
 
 
08.068 Dec-(5- and 6)-enoic acid 
OH
O
OH
O
(E)-isomers shown  
3742 
 
72881-27-7 
327 
JECFA specification (JECFA, 
2000b) 
3.4 Category N c) 
No safety concern d) 
 
JECFA evaluated 5 & 6-decenoic 
acid (mixture) (CASrn as in 
Register). CASrn in Register 
refers to incompletely defined 
substance. 
08.070 3-Methylcrotonic acid 
OH
O
 
3187 
10138 
541-47-9 
1204 
JECFA specification (JECFA, 
2003). 
0.012  
No safety concern a) 
 
 
08.079 4-Ethyloctanoic acid 
OH
 
3800 
 
16493-80-4 
1218 
JECFA specification (JECFA, 
2005). 
0.73  
No safety concern a) 
 
 
09.011 Geranyl acetate 
O
O
 
2509 
201 
105-87-3 
58 
JECFA specification (JECFA, 
2001) 
470  
No safety concern e) 
Category A b) 
GrADI: 0-0.5 (JECFA, 1980). 
09.012 Citronellyl acetate 
O
O
 
2311 
202 
150-84-5 
57 
JECFA specification (JECFA, 
2003). (R) or (S) enatiomer not 
specified by CASrn in Register 
190  
No safety concern e) 
Category A b) 
GrADI: 0-0.5 (JECFA, 1980). R- 
or S-enantiomer not specified by 
CASrn in Register. 
09.033 Rhodinyl acetate 
O
O
 
2981 
223 
141-11-7 
60 
JECFA specification (JECFA, 
2003) 
0.97  
No safety concern e) 
Deleted b) 
CASrn in Register refers to 3,7-
dimethyl-7-octen-1-ol-1-acetate; 
(R)- or (S)-enantiomer not 
specified by CASrn in Register. 
Register name corresponds to 
CASrn 9448-73-9; which is the 
(S)-enantiomer. 
09.048 Geranyl butyrate 
O
O
 
2512 
274 
106-29-6 
66 
JECFA specification (JECFA, 
2003) 
52  
No safety concern e) 
Category A b) 
 
09.049 Citronellyl butyrate 
OO  
2312 
275 
141-16-2 
65 
JECFA specification (JECFA, 
2003) 
27  
No safety concern e) 
Category A b) 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.067 Geranyl hexanoate O
O  
2515 
317 
10032-02-7 
70 
JECFA specification (JECFA, 
2001) 
0.061  
No safety concern e) 
Category A b) 
 
09.076 Geranyl formate 
OO  
2514 
343 
54 
JECFA specification (JECFA, 
280  
No safety concern e) 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
105-86-2 2003) Category A b) 
09.078 Citronellyl formate 
O O  
2314 
345 
105-85-1 
53 
JECFA specification (JECFA, 
2005) 
87  
No safety concern e) 
Category A b) 
GrADI: 0-0.5 (JECFA, 1980). R- 
or S-enantiomer not specified by 
CASrn in Register. 
09.079 Rhodinyl formate 
O
O
 
2984 
346 
141-09-3 
56 
JECFA specification (JECFA, 
2003) 
0.061  
No safety concern e) 
Deleted b) 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.128 Geranyl propionate 
O
O
 
2517 
409 
105-90-8 
62 
JECFA specification (JECFA, 
2003) 
69  
No safety concern e) 
Category A b) 
 
09.129 Citronellyl propionate O
O  
2316 
410 
141-14-0 
61 
JECFA specification (JECFA, 
2003) 
35  
No safety concern e) 
Category A b) 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.141 Rhodinyl propionate 
O
O
 
2986 
422 
105-89-5 
64 
JECFA specification (JECFA, 
2001) 
ND  
No safety concern e) 
Deleted b) 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.151 Citronellyl valerate 
O
O
 
2317 
469 
7540-53-6 
69 
JECFA specification (JECFA, 
2000b) 
0.61  
No safety concern e) 
Category A b) 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.167 Neryl butyrate 
O
O
 
2774 
505 
999-40-6 
67 
JECFA specification (JECFA, 
1997b) 
0.35  
No safety concern e) 
Category B b) 
 
09.169 Neryl propionate 
O
O
 
2777 
509 
105-91-9 
63 
JECFA specification (JECFA, 
1997b) 
3.7  
No safety concern e) 
Category B b) 
 
09.191 Ethyl hex-3-enoate 
O
O
(Z)-isomer shown  
3342 
 
2396-83-0 
335 
JECFA specification (JECFA, 
1998b) 
3.2  
No safety concern d) 
 
JECFA evaluated ethyl-3-
hexenoate (CASrn as in 
Register). (Z)- or (E)-isomer not 
specified by CASrn in Register. 
09.192 Ethyl oleate 
O
O
 
2450 
633 
111-62-6 
345 
JECFA specification (JECFA, 
1998b) 
60  
No safety concern d) 
Category A b) 
 
09.212 Neryl formate 
O
O
 
2776 
2060 
2142-94-1 
55 
JECFA specification (JECFA, 
2005) 
0.0061  
No safety concern e) 
Category B b) 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.213 Neryl acetate 
O
O
 
2773 
2061 
141-12-8 
59 
JECFA specification (JECFA, 
1997b) 
150  
No safety concern e) 
Category B b) 
 
09.236 Methyl undec-9-enoate 
O
O
(E)-isomer shown  
2750 
2101 
5760-50-9 
342 
JECFA specification (JECFA, 
2000) 
34  
No safety concern d) 
Deleted b) 
JECFA evaluated methyl 9-
undecanoate (CASrn as in 
Register). (Z)- or (E)-isomer not 
specified by CASrn in Register. 
09.237 Ethyl undec-10-enoate 
O
O
 
2461 
10634 
692-86-4 
343 
JECFA specification (JECFA, 
1998b) 
1.5  
No safety concern d) 
Deleted b) 
 
09.238 Butyl undec-10-enoate 
O
O
 
2216 
2103 
109-42-2 
344 
JECFA specification (JECFA, 
2001) 
0.037  
No safety concern d) 
Category B b) 
 
09.265 Ethyl oct-4-enoate 
O
O
 
3344 
10619 
34495-71-1 
338 
JECFA specification (JECFA, 
2003) 
1.2  
No safety concern d) 
 
JECFA evaluated ethyl cis-4-
octenoate (CASrn as in Register). 
CASrn in Register refers to (Z)-
isomer. Register name to be 
changed to Ethyl oct-4Z-enoate. 
09.267 Methyl hex-3-enoate 
O
O
(E)-isomer shown  
3364 
10801 
2396-78-3 
334 
JECFA specification (JECFA, 
2001) 
0.56  
No safety concern d) 
 
Z- or E-isomer not specified by 
name and CASrn in Register. 
09.268 Methyl oct-4(cis)-enoate 
O
O
 
3367 
10834 
21063-71-8 
337 
JECFA specification (JECFA, 
2003) 
0.37  
No safety concern d) 
 
 
09.273 Isobutyl crotonate 
O
O
 
3432 
10706 
589-66-2 
1206 
JECFA specification (JECFA, 
2003). 
0.46  
No safety concern a) 
 
 
09.284 Ethyl dec-4-enoate 
O
O
 
3642 
10578 
76649-16-6 
341 
JECFA specification (JECFA, 
2000b) 
1.8  
No safety concern d) 
 
JECFA evaluated ethyl trans-4-
decenoate (CASrn as in 
Register). CASrn refers to (E)-
isomer. Register name to be 
changed to E-Ethyl dec-4-enoate. 
09.290 Ethyl octa-4,7-dienoate 
O
O
 
3682 
 
69925-33-3 
339 
JECFA specification (JECFA, 
2000d) 
1.8  
No safety concern d) 
 
JECFA evaluated ethyl cis-4,7-
octadienoate (CASrn as in 
Register). CASrn in Register 
refers to the (Z)-isomer. Register 
name to be changed to Ethyl 
octa-4Z,7-dienoate. 
09.291 Hex-3-enyl hex-3-enoate 
O
O
 
3689 
 
61444-38-0 
336 
JECFA specification (JECFA, 
1998b) 
3.2  
No safety concern d) 
 
JECFA evaluated cis-3-hexenyl 
cis-3-hexenoate (CASrn as in 
Register). CASrn in Register 
refers to the (Z)/(Z)-isomer. 
Register name to be changed to 
Hex-3Z-enyl hex-3Z-enoate. 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.298 Methyl non-3-enoate 
O
O
(E)-isomer shown  
3710 
 
13481-87-3 
340 
JECFA specification (JECFA, 
2000b) 
1.6  
No safety concern d) 
 
JECFA evaluated methyl 3-
nonenoate (CASrn as in 
Register). (Z)- or (E)-isomer not 
specified by CASrn in Register. 
09.408 Isobutyl 2-methylbut-2(cis)-
enoate 
O
O
 
2180 
247 
7779-81-9 
1213 
JECFA specification (JECFA, 
2003). 
0.12  
No safety concern a) 
Category B b) 
 
09.421 Citronellyl isobutyrate 
O
O
 
2313 
296 
97-89-2 
71 
JECFA specification (JECFA, 
2003) 
11  
No safety concern e) 
Category A b) 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.424 Neryl isobutyrate 
O
O
 
2775 
299 
2345-24-6 
73 
JECFA specification (JECFA, 
2003) 
1.7  
No safety concern e) 
Category B b) 
 
09.431 Geranyl isobutyrate 
O
O
 
2513 
306 
2345-26-8 
72 
JECFA specification (JECFA, 
2001) 
110  
No safety concern e) 
Category B b) 
 
09.453 Geranyl isovalerate O
O  
2518 
448 
109-20-6 
75 
JECFA specification (JECFA, 
2000b) 
41  
No safety concern e) 
Category B b) 
 
09.465 Rhodinyl isovalerate 
O
O
 
2987 
460 
7778-96-3 
77 
JECFA specification (JECFA, 
2001) 
0.012  
No safety concern e) 
Deleted b) 
CASrn in Register refers to 3S-
enantiomer. 
09.471 Neryl isovalerate 
O
O
 
2778 
508 
3915-83-1 
76 
JECFA specification (JECFA, 
1997b) 
0.024  
No safety concern e) 
Category B b) 
 
09.515 Geranyl 2-ethylbutyrate 
O
O
 
3339 
11667 
73019-14-4 
78 
JECFA specification (JECFA, 
2001) 
0.49  
No safety concern e) 
 
 
09.517 Methyl citronellate O
O
 
3361 
10781 
2270-60-2 
354 
JECFA specification (JECFA, 
2000b) 
0.13  
No safety concern d) 
 
R- or S-enantiomer not specified 
by CASrn in Register. 
09.524 Ethyl 2-methylpent-3-enoate 
O
O
(Z)-isomer shown  
3456 
10612 
1617-23-8 
350 
JECFA specification (JECFA, 
2001) 
4.9  
No safety concern d) 
 
JECFA evaluated ethyl 2-methyl-
3-pentenoate (CASrn as in 
Register). (Z)- or (E)-isomer nor 
(R) or (S) enantiomer not 
specified by Register CASrn. 
09.527 Ethyl 2-methylpent-4-enoate 
O
O
 
3489 
10613 
53399-81-8 
351 
JECFA specification (JECFA, 
1998b) 
0.024  
No safety concern d) 
 
(R) or (S) enantiomer not 
specified by Register CASrn. 
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Table 8: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.540 Ethyl 2-methylpenta-3,4-
dienoate 
O
O
 
3678 
 
60523-21-9 
353 
JECFA specification (JECFA, 
2000b). 
0.012  
No safety concern f) 
 
(R) or (S) enantiomer not 
specified by Register CASrn. 
09.546 Hexyl-2-methylpent-(3 and 4)-
enoate 
O
O
O
O
(Z)-isomer shown
 
3693 
 
58625-95-9 
352 
JECFA specification (JECFA, 
2001) 
0.024  
No safety concern d) 
 
JECFA evaluated hexyl 2-methyl-
3&4-pentenoate (mixture) 
(CASrn as in Register). Register 
CASrn refers to the (E)-isomer. 
(R) or (S) enantiomer not 
specified by Register CASrn. 
09.571 Hex-3-enyl valerate O
O
(Z)-isomer shown  
3936 
10686 
35852-46-1 
1278 
JECFA specification (JECFA, 
2003). 
6.1  
No safety concern a) 
 
JECFA evaluated cis-3-hexenyl 
valerate (CASrn as in Register). 
Register CASrn refers to the (Z)-
isomer.  
09.646 Methyl linolenate 
O
O
 
3411 
714 
301-00-8 
346 
JECFA specification (JECFA, 
2003) 
ND  
No safety concern d) 
Category A b) 
JECFA evaluated a mixture of 
methyl linoleate and methyl 
linolenate (CASrn as in Register). 
Register CASrn refers to the 
(Z)/(Z)/(Z)-isomer (i.e. methyl 
linolenate). 
09.655 3-Methylbut-3-enyl acetate 
O
O
 
3991 
 
5205-07-2 
1269 
JECFA specification (JECFA, 
2003). 
7.3  
No safety concern a) 
 
 
09.927 Rhodinyl butyrate 
O
O
 
2982 
 
141-15-1 
68 
JECFA specification (JECFA, 
2005) 
ND  
No safety concern e) 
 
 
09.940 Rhodinyl isobutyrate 
O
O
 
2983 
 
138-23-8 
74 
JECFA specification (JECFA, 
2001) 
0.012  
No safety concern e) 
 
JECFA CASrn 1338-23-8 not 
valid. 
16.001 Ammonium isovalerate 
O-NH4+
O
 
2054 
464 
7563-33-9 
1203 
JECFA specification (JECFA, 
2005). 
15  
No safety concern a) 
Deleted b) 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2004a). 
b) (CoE, 1992). 
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c) (SCF, 1995). 
d) (JECFA, 2000a). 
e) (JECFA, 1999b). 
f) (JECFA, 2007). 
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TOXICITY TABLES 
Table 9: Acute Toxicity 
Acute toxicity data are available for four candidate substances of the present Flavouring Group Evaluation and for 53 supporting and structurally related 
substances evaluated by the JECFA at the 49th, 51st and 61st meetings (JECFA, 1998a; JECFA, 1999a; JECFA, 2004b). The supporting substances are listed 
in brackets. 
 
Table 9: ACUTE TOXICITY 
Chemical Name [FL-no] Species Sex Route LD50 (mg/kg bw) Reference Comments 
(4-Pentenoic acid [08.048]) Mouse NR Gavage 610 (Jenner et al., 1964)  
Rat M/F Gavage 470 (Jenner et al., 1964)  
Pent-4-enal [05.174] Rat F Gavage 620 (Smyth et al., 1962)  
(cis-3-Hexen-1-ol [02.056]) Mouse M Gavage 7000 (Gaunt et al., 1969)  
Mouse F Gavage 7200 (Gaunt et al., 1969)  
Rat M/F Oral 4700 (Moreno, 1973c)  
Rat M Gavage 10100 (Gaunt et al., 1969)  
Rat F Gavage 7300 (Gaunt et al., 1969)  
(cis-3-Hexenal [05.075]) Rat M/F Gavage 1560 (Palanker and Lewis, 1979)  
((Z,Z)-3,6-Nonadien-1-ol1 [02.189]) Rat M/F Oral 2000 (Koike, 1996)  
(cis-6-Nonenal [05.059]) Mouse NR Oral 5000 (Moreno, 1978b)  
(9-Decenal1 [05.139]) Mouse M/F Gavage 9500 (Johnson, 1980) LD50 > 5 ml/kg. 
(10-Undecenal [05.035]) Rat NR Oral 5000 (Hart and Wong, 1971)  
(10-Undecenoic acid [08.039]) Mouse NR Gavage  8150 (Newell et al., 1949)  
Mouse NR Oral 2300-6600 (Tislow et al., 1950)  
Rat NR Oral 2500 (Tislow et al., 1950)  
(Oleic acid [08.013]) Rat NR Oral 5000 (Moreno, 1977b)  
Rat NR Oral 19000 (Briggs et al., 1976) LD50 was > 21.5 ml for octadecanoic acid (75 % oleic 
acid) & octadecadienoic acid (53 % linoleic acid, 
23 % oleic acid). 
(cis-3-Hexenyl propionate1 [09.564]) Rat NR Oral 5000 (Moreno, 1976a)  
(cis-3-Hexenyl valerate1) Rat NR Oral 5000 (Moreno, 1978b) 1/10 rats died after a dose of 5000 mg/kg. 
(Ethyl cis-4,7-octadienoate [09.290]) Rat M/F Gavage 10000 (Mondino, 1979)  
(Methyl 9-undecenoate [09.236]) Rat M Oral 3000 (Moreno, 1977b)  
(Ethyl 10-undecenoate [09.237]) Rat NR Oral 5000 (Moreno, 1977b)  
(Butyl 10-undecenoate [09.238]) Rat NR Oral 5000 (Moreno, 1977b)  
(Ethyl oleate [09.192]) Rat NR Oral 5000 (Bailey, 1976) 1/10 rats died after a dose of 5000 mg/kg. 
3-Methyl-but-3-en-1-ol [02.176] Rat NR Oral 5440 (BASF, 1968)  
(2,6-Dimethyl-5-heptenal [05.074]) Rat NR Oral 5000 (Levenstein, 1974)  
Rat M/F Gavage 4550 (Mayyasi et al., 1981) LD50 > 5 ml/kg. 
Lavandulol [02.170] Mouse NR Oral 5000 (Moreno et al., 1982) 4/10 mice died after a dose of 5000 mg/kg. 
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Table 9: ACUTE TOXICITY 
Chemical Name [FL-no] Species Sex Route LD50 (mg/kg bw) Reference Comments 
(3-Hexenyl isobutyrate1 [09.563]) Rat  M/F Gavage 25000 (Moran et al., 1980)  
Mouse M/F Gavage  25000 (Moran et al., 1980)  
(Hexyl 2-methyl-3&4-pentenoate [09.546]) Rat M/F Gavage 5000 (Elleman, 1979)  
(Ethyl 2-methyl-3,4-pentadienoate [09.540]) Mouse M Gavage 1316 (Babish, 1978)  
Mouse F Gavage 892 (Babish, 1978)  
Mouse M/F Gavage 770 (Moran et al., 1980)  
(Citronellyl formate [09.078]) Rat M/F Gavage 8400 (Calandra, 1971)  
(Geranyl formate [09.076]) Rat M/F Gavage 5460 (Weir and Wong, 1971) LD50 > 6 ml/kg. 1/5 rats died after 6 ml/kg. 
(Neryl formate [09.212]) Rat NR Oral  5000 (Moreno, 1975)  
(Rhodinyl formate [09.079]) Rat NR Oral  5000 (Moreno, 1974a) 1/10 rats died after a dose of 5000 mg/kg. 
(Citronellyl acetate [09.012]) Rat M/F Gavage 6800 (Calandra, 1971)  
(Geranyl acetate [09.011]) Rat M/F Gavage 6330 (Jenner et al., 1964)  
(Neryl acetate [09.213]) Rat M/F Gavage 4550 (Levenstein and Wolven, 1972a) LD50 > 5 ml/kg. 
(Rhodinyl acetate [09.033]) Rat M/F Gavage 5000 (Levenstein, 1973) LD50 > 5 ml/kg. 
(Citronellyl propionate [09.129]) Rat NR Oral 5000 (Moreno, 1973a) 3/10 rats died after a dose of 5000 mg/kg. 
(Geranyl propionate [09.128]) Rat NR Oral 5000 (Russell, 1973)  
(Neryl propionate [09.169]) Rat NR Oral 5000 (Moreno, 1975)  
(Rhodinyl propionate [09.141]) Rat NR Oral 5000 (Moreno, 1976b)  
(Citronellyl butyrate [09.049]) Rat NR Oral 5000 (Moreno, 1972) 3/10 rats died after a dose of 5000 mg/kg. 
(Geranyl butyrate [09.048]) Rat M/F Gavage 10660 (Jenner et al., 1964)  
(Rhodinyl butyrate [09.927]) Rat NR Oral 5000 (Moreno, 1975)  
(Geranyl hexanoate [09.067]) Rat NR Oral 5000 (Moreno, 1975)  
(Citronellyl isobutyrate [09.421]) Rat NR Oral 5000 (Denine and Palanker, 1973)  
(Geranyl isobutyrate [09.431]) Rat NR Oral 5000 (Shelanski and Moldovan, 1973)  
(Neryl isobutyrate [09.424]) Rat M Oral 5000 (Moreno, 1980a)  
(Rhodinyl isobutyrate [09.940])  Rat NR Oral 5000 (Moreno, 1975)  
(Geranyl isovalerate [09.453]) Rat NR Oral 5000 (Levenstein, 1975)  
(Geranyl 2-ethylbutanoate [09.515]) Mouse NR Oral 8000 (Pellmont et al., 1968)  
Undec-10-e(n-1-ol [02.125] Rat M/F Oral 5000 (Levenstein and Wolven, 1972b) LD50 > 5 ml/kg. 
(2-Methylbutan-1-ol [02.076]) Rat NR Oral 4010 (Rowe and McCollister, 1982)  
(3-Methylbut-2-en-1-ol [02.109]) Rat NR Oral 810 (Moreno, 1977a) Cited in JECFA, 2004b. Data not available to EFSA. 
(2-Methylcrotonic acid [08.064] Mouse NR Oral 1150 (Schafer and Bowles, 1985)  
(2-Methyl-2-pentenoic acid [08.055]) Rat M Oral < 5000 (Moreno, 1980b) Cited in JECFA, 2004b. Data not available to EFSA. 
(Citronellol [02.011]) Rat NR Oral 3450 (Moreno, 1973b)  
(Citronellal 05.021) Rat  NR Oral >5000 (Moreno, 1973b)  
(Citronellic acid [08.036]) Rat NR Oral. 2610 (Moreno, 1978c) Cited in JECFA, 2004b. Data not available to EFSA. 
(Rhodinol [02.027]) Rat  NR Oral >5000 (Moreno, 1973b)  
(Geraniol [02.012]) Rat M, F Oral 3600 (Jenner et al., 1964)  
Rat  NR Oral 4800 (Yamawaki, 1962)  
(Citral [05.020]) Mouse M, F Oral 3297 (Hoffman-LaRoche Inc., 1967a)  
Mouse M Oral 2007 (Hoffman-LaRoche, Inc., 1967b)  
Mouse M, F Oral 2464 (Hoffman-LaRoche, Inc., 1967b)  
Rat M, F Oral 4960 (Jenner et al., 1964)  
Rat NR Oral 6800 (Hofmann, 1978)  
(3,7,11-Trimethyldodeca-2,6,10-trien-1-ol [02.029]) Mouse M, F Oral 8764 (Hoffman-LaRoche Inc., 1967a)  
Rat M, F Oral > 5000 (Gelbke, 1981)  
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Table 9: ACUTE TOXICITY 
Chemical Name [FL-no] Species Sex Route LD50 (mg/kg bw) Reference Comments 
Rat NR Oral >5000 (Moreno, 1974b)  
Rat M, F Oral >20 ml/kg (17742)2 (Sterner and Stiglic, 1976) Cited in JECFA, 2004b. Data not available to EFSA. 
NR: Not Reported 
1 A substance evaluated at the 61st JECFA meeting structurally related to candidate substances in FGE.06. 
2 Calculated using a density of 0.8871.(Merck Index, 1997). 
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Table 10:  Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Subacute / subchronic / chronic /carcinogenicity toxicity data are available for 14 supporting and structural related substances of the present flavouring group. 
They were evaluated at the 49th, 51st and 61st JECFA meetings (JECFA, 1998a; JECFA, 1999a; JECFA, 2004b). No repeated dose studies are available on the 
candidate substances. The supporting substances are listed in brackets. 
Table 10: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL  
(mg/kg bw/day) 
Reference Comments 
(cis-3-Hexen-1-ol [02.056]) Rat; M, F 
30 
Drinking water 0, 310, 1250, 5000 
ppm equal to M: 0, 
30, 127, 410 mg/kg 
bw/day, F: 0, 42, 168, 
721 mg/kg bw/day 
98 days 127-168 (Gaunt et al., 1969) NOAEL corresponds to 1250 mg/kg feed. 
 
(10-Undecenoic acid [08.039]) Rat; M, F 
NR 
Gavage 0, 100, 200 and 400 
mg/kg bw/day 
6 months 400 (Tislow et al., 1950) Total number of animals studied was 152. 
Endpoints included body weight and changes in 
autopsy (only poorly reported abstract available). 
Rat; M 
7 
Diet 0, 5000, 10000 and 
25000 mg/kg feed 
equivalent to 0, 500, 
1000 and 2500 mg/kg 
bw/day 
8 weeks 25002  (Newell et al., 1949) Reported only data on body weight. Study ongoing 
at the reporting time. There was a reduction in body 
weight gain at both concentration. Doses are 
considered very high. 
(Oleic acid [08.013]) Rabbit; M, F 
20 
Diet 0, 150000 mg/kg feed 
equivalent to 4500 
mg/kg bw/day 
36 weeks 45002 (Borgman and Wardlaw, 
1975) 
Groups: (1) olive oil and (2) semipurified oleic acid. 
Treatment included periods with diet supplemented 
with cholesterol. Serum cholesterol was the main 
endpoint. Rabbits fed oleic acid began to deteriorate 
by week 17th. Animals showed severe to slight 
hepatic fatty acid degeneration. 
Mouse; NR 
36 and 55 
Diet 0, 1500 mg/kg feed 
equivalent to 0, 225 
mg/kg bw/day 
24 months 2252 (El-Khatib and Cora, 1981) Groups were given (1) normal diet, or (2) normal 
diet + corn oil (10 %) + oleic acid (0.15 %). Main 
endpoint was lipid content in the liver and pituitary 
gland. There was an increase. In 3 of 36 surviving 
mice given diet with corn oil + oleic acid 
adenocarcinoma of the colon was reported. 
Rabbit; M, F 
38-42 
Diet 0, 150000 mg/kg feed 
equivalent to 0, 4500 
mg/kg bw/day 
16 weeks 45002 (Lee et al., 1986) Treated animals were given a diet with 40 % casein 
and 15 % oleic acid. Examined for gallbladder 
content. The treated animals showed gallstones. 
(Oleic acid/linoleic acid mixture [08.013] / 
[08.041]) 
 
Mouse; M, F 
329-623 
Oral (given on a 
separate dish) 
0, 0 and ~ 64-100 
mg/kg bw/day 
≈ 24 months (long 
term, exact duration 
not reported) 
 64-100 (Szepsenwol and 
Boschetti, 1975) 
A NOAEL was not determined. Groups: (1) 
untreated (2) refined corn oil, (3) refined corn oil 
with 15 mg/g oleic acid/linoleic acid mixture. Mice 
given treatment (3) had a higher incidence of 
stomach tumours as compared to the other two 
groups. 
Mouse; NR 
195-328 
Oral (given on a 
separate dish) 
0, 0, 0 and ~ 85-100 
mg/kg bw/day 
≈ 24 months (long 
term, exact duration 
not reported) 
 85-100 (Szepsenwol, 1978) A NOAEL was not determined. Groups: (1) 
untreated, (2) refined corn oil, (3) crude corn oil, 
and (4) refined corn oil + oleic acid/linoleic acid 
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Table 10: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL  
(mg/kg bw/day) 
Reference Comments 
mixture. The mixture oleic acid/linoleic acid was 
carcinogenic, with an increased incidence of 
forestomach papilloma, squamous cell carcinoma 
and pyloric tumours. 
(Hexanoic acid1 [08.009]) Rat; M, F 
10 
Diet 100000 mg/kg feed 
equivalent to 5000 
mg/kg bw/day 
5 months 50002 (Mori, 1953) Endpoint was gastric lesions. No attempt was made 
to estimate the amount ingested by rats due to the 
volatility of fatty acid, which raises concerns on the 
validity of the results. 
(2,6-Dimethyl-5-heptenal [05.074]) Rat; M, F 
30 
Diet 0, 9, 37 and 150 
mg/kg bw/day 
3 months 37 (Gaunt et al., 1983)  
(2-Ethylbutyric acid1 [08.045]) Rat; M, F 
6 
Diet 6000 mg/kg feed 
equivalent to 300 
mg/kg bw/day 
3 months 3002 (Amoore et al., 1978)  
(Citronellyl acetate and geranyl acetate 
[09.012] and [09.011]) 
Mouse; M, F 
20 
Gavage 0, 125, 500, 1000 and 
2000 mg/kg bw/day 
13 weeks 1000 (NTP, 1987) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate.  
Rat; M, F 
20 
Gavage 0, 250, 500, 1000, 
2000 and 4000 mg/kg 
bw/day 
13 weeks 2000 (NTP, 1987) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate. 
Mouse; M, F 
100 
Gavage 0, 500 and 1000 
mg/kg bw/day 
2 years  500 (NTP, 1987) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate. Survival among 
males was 62, 64 and 0 %, respectively. Survival 
among females was 50, 30 and 0 %, respectively. 
The mixture was not considered to be carcinogenic. 
Rat; M, F 
100 
Gavage 0, 1000 and 2000 
mg/kg bw/day 
2 years  1000 (NTP, 1987) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate. Survival among 
males was 68, 58 and 36 %. Survival among 
females was 70, 56 and 66 %, respectively. The 
mixture was not considered carcinogenic. 
(Geranyl acetate [09.011]) Rat; M, F 
20 
Diet 0, 1000, 2500 and 
10000 mg/kg feed 
equivalent to 0, 50, 
125, 500 mg/kg 
bw/day 
17 weeks 5003 (Hagan et al., 1967)  
(Geraniol [02.012]) Rat; M, F 
10 
Diet 0, 10000 mg/kg feed 
equivalent to 500 
mg/kg bw/day 
16 weeks 5002 (Hagan et al., 1967)  
Rat; M, F 
10 
Diet 0, 1000 mg/kg feed 
equivalent to 50 
mg/kg bw/day 
27 – 28 weeks 502 (Hagan et al., 1967)  
(Citronellol [02.011]) Rat; M, F 
30 
Diet Incompletely reported 12 weeks 50 (Oser, 1958) 
 
The test material was a mixture consisting of equal 
amounts of citronellol and linalool. The publication 
was not provided, only a FAO report referring to it. 
There was a slightly retarded growth of males, 
without effect on food utilization. No other 
endpoints are mentioned. 
(Citral [05.020]) Mouse; M, F 
10 
Gavage 3 0, 534, 1068 and 
2137 mg/kg bw/day 
12 days <534 (Dieter et al., 1993) All mice at the highest dose level and two males at 
1068 mg/kg bw/day died. There was a dose-related 
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Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL  
(mg/kg bw/day) 
Reference Comments 
 increase in liver weights in both females and males 
with cytoplasmic fatty vacuolization of 
hepatocytesin females at the mid and highest doses 
and in males at the highest dose. Necrosis, 
ulceration, and acute inflammation of the 
forestomach were observed at the higher doses. 
 
 
Mouse; M, F 
10 
Diet4 0, 534, 1068, 2137, 
4275 and 8550 mg/kg 
bw/day 
14 days 4275 (Dieter et al., 1993) The only effect seen was decreased body weights in 
both males and females at the highest dose level 
given. 
Mouse; M, F 
20 
Diet 4 0, 745, 1840, 3915 
and 8110 mg/kg bw 
for males. 
0, 790, 1820, 3870 
and 7550 mg/kg bw 
for females 
14 weeks <745(M) 
<790(F) 
(NTP, 2003) Decreased body weights and body-weight gains, 
and reductions in lymphocyte and leukocyte counts 
in males, and decreased body weights and body-
weight gains in females at all dose levels. 
 
Rat; M, F 
10 
Gavage3 0, 570, 1140 and 
2280 mg/kg bw/day 
 
12 days 1140(M) 
2280(F) 5 
(Dieter et al., 1993) All rats survived the duration of the study. No 
effects on neither final body weights nor organ 
weights. Mild hyperplasia of the squamous 
epithelium of the forestomach was seen in two 
males receiving the highest dose. 
 
Rat; M, F 
10 
Diet3 0, 142, 285, 570, 
1140 and 2280 mg/kg 
bw/day 
 
14 days 570 (Dieter et al., 1993) Reduced bodyweight gain in males and females at 
the two highest doses. The absolute weights of the 
liver, kidney and spleen were decreased in males 
and females at the highest dose. Minimal to mild 
hyperplasia and/or squamous metaplasia of the 
respiratory epithelium of the anterior portion of the 
nasal passages of rats at the two highest doses. 
 
Rat; M, F 
21 
Diet  0 and 52 mg/kg 
bw/day for males 
0 and 60 mg/kg 
bw/day for females 
12 weeks 52(M)5,6 
60(F) 5,6 
(Oser, 1958) Citral was given together with an equal amount of 
citral diethylacetal. No effects were reported. The 
study is considered to be of limited validity. 
Rat; M, F 
20 
Diet 0, 50, 125 and 500 
mg/kg bw/day 
13 weeks 5005,7 (Hagan et al., 1967) No treatment-related effects on growth, 
haematology and organ weights were observed, and 
there were no macroscopic or microscopic changes 
in the tissues. The Panel noted the limited reporting 
of the study. 
 
Rat; M, F 
20 
Diet4 0, 345, 820 and 1785 
mg/kg bw for males 
0, 335, 675 and 1330 
mg/kg bw for females 
14 weeks <345(M) 
675(F) 
(NTP, 2003) Increased incidences of nephropathy were seen in 
males at all dose levels. Decreased body weights 
and body-weight gains, and bone marrow atrophy 
accompanied accompanied by bone marrow 
haemorrhage in females at the highest dose. 
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Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL  
(mg/kg bw/day) 
Reference Comments 
 
Mouse; M, F 
100 
Diet4 0, 50, 100 and 210 
mg/kg bw/day 
104-105 weeks 120(M) 
60(F) 
(NTP, 2003) The study is considered valid. 
The NOAEL was 120 mg/kg bw/day based on  
reduced mean body weight at the highest dose. 
Citral was not considered to be carcinogenic. 
Rat; M, F 
100 
Diet4 0, 60, 120 and 260 
mg/kg bw/day 
104-105 weeks 100 (NTP, 2003) The study is considered valid. 
Mean body weights of females in all dosed groups 
were lower than controls. Otherwise no treatment 
related effects were shown. Citral was not 
considered to be carcinogenic. 
(2,4-Dimethylpent-2-enoic acid [08.044]) Rat; M, F 
28 
Diet8 0 and 1.36 mg/kg 
bw/day for males 
0 and 1.55 mg/kg 
bw/day for females. 
13 weeks 1.36(M)5 
1.55(F)5 
(Posternak, 1968) No significant toxicological effects were reported. 
(Citronellyl isobutyrate [09.421]) Rat; M, F 
28 
Diet 0, 14.7 mg/kg bw/day 3 months 14.7 (Damske et al., 1980)  
NR = Not Reported. 
NA = Not Applicable.  
1 A substance evaluated at the 49th JECFA meeting and structurally related to candidate substances in FGE.06. 
2 Conversion table for test chemical treatment dosed used in PAFA (FDA, 1993). 
3 Administered in corn oil. 
4 Administered microencapsolaetd in the diet. 
5 As neither a single dose nor multiple doses had any adverse effects. 
6 Dose given for citral. 
7 Administered as a mixture of citral and citral diethyl acetal (1 : 1, w/w). 
8 Administered in an emulsion with gum arabic. 
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Table 11:  Developmental / Reproductive Toxicity Studies 
No developmental and reproductive toxicity studies are available for any candidate substance in the present flavouring group. Studies were available for two 
supporting substance and one study for a hydrolysis product. 
Table 11: Developmental / Reproductive Toxicity Studies 
Chemical name Study type 
Duration 
Species/sex  
No/group 
Route Dose levels NOAEL 
mg/kg/day 
Including information on 
possible maternal toxicity 
Reference Comments 
(10-Undecenoic acid [08.039]) One generation study 
9 months  
Rat; M, F 
NR 
Gavage  
 
NR NR (Tislow et al., 1950) Only poorly reported 
abstract available. 
(2-Ethylbutyric acid [08.045]) Developmental toxicity; dose 
administered gestation days 6-15 
Rat; F 
9-18 
gavage 0, 150, 200 mg/kg bw 200 (Narotsky et al., 1994)  
Developmental toxicity; dose 
administered gestation day 8 
Mouse; F 
15/group 
Subcutaneos 
injection 
0, 600 mg/kg bw < 600 (Nau and Löscher, 1986) 1 
(Citral [05.020]) Developmental/reproductive toxicity; 
dose administration two weeks prior to 
mating until day 20 of gestation (15 per 
group) or until weaning (15 per group) 
Rat, F 
30 
Gavage 0, 50, 160 and 500 mg/kg bw/day 50: maternal toxicity 
160: developmental toxicity 
(Hoberman et al., 1989) Maternal toxicity at the 
two highest dose groups. 
Significantly decreased 
pup body weights 
reported at the highest 
dose. No change in 
reproductive parameters. 
Only available as an 
poorly reported abstract. 
Developmental toxicity; dose 
administered gestation days 6-15 
Rat, F 
 
Gavage 0, 60, 125, 250, 500, or 1000 
mg/kg bw/day 
60  (Nogueira et al., 1995) Signs of fetal growth 
retardation and a higher 
incidence of minor 
skeletal abnormalities at 
doses higher than 60 
mg/kg bw/day. 
NR = Not Reported. 
1) In the present study valproic acid as well as a number of related substances was examined with respect to their teratogenic potential. Valproic acid was highly teratogenic at 600 mg/kg/day. The study showed that the teratogenic potential 
increased with the number of carbon-atoms in the 2-position. 
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Table 12:  Genotoxicity (in vitro) 
In vitro mutagenicity/genotoxicity data are available for one candidate substances of the present Flavouring Group Evaluation and for 12 supporting 
substances evaluated at the 49th, 51st and 61st JECFA meetings (JECFA, 1998a; JECFA, 1999a; JECFA, 2004b). Supporting substances are listed in brackets. 
Table 12: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test system Test Object Concentration Result Reference Comments 
 
(Citronellol [02.011]) Reverse mutation S. typhimurium  
TA98 and TA100 
0.05-100 µl/plate 
(0.04-85 µg/plate) 
Negative4 (Rockwell and Raw, 1979) 
 
Invalid poorly reported study. 
Rec assay B. subtilis 
 M45 and H17 
17 µg/disk Negative (Oda et al., 1979) 
 
The test system used is considered inappropriate; 
insufficient validity. 
(Geraniol [02.012)] 
Reverse mutation S. typhimurium TA 100 0.01-1.0 µl 
(8.89–889 mg/tube)9 
Negative2 (Eder et al., 1980)  
Limited validity; poorly reported study. 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate 
(463 µg/plate)8 
Negative2 (Florin et al., 1980)  
Insufficient validity (spot test, not according to 
OECD guideline, methods and results 
insufficiently reported). 
Reverse mutation S. typhimurium TA92, 
TA94, TA98, TA100, 
TA1535, TA1537 
<500 µg/plate Negative4 (Ishidate et al., 1984)  
Valid. According to current guidelines.The study 
is considered valid. 
Sister chromatid 
exchange 
Chinese hamster ovary cells 33.3–333 µmol/l  
(5.14–51.4 µg/ml)8 
Negative3 (Sasaki et al., 1989)  
Limited valitity. Tested for enhancing effect on 
Mitomycin C. 
Chromosomal 
aberration 
Chinese hamster fibroblast 
cells 
<125 µg/ml Negative3,6 (Ishidate et al., 1984)  
Limited validity (performed only in the absence 
of metabolic activation). 
Rec assay B. subtilis M45 and H17 16 µg/disk Negative (Oda et al., 1979)  
The test system used is considered inappropriate; 
insufficient validity. 
(3,7,11-Trimethyldodeca-2,6,10-trien-1-ol 
[02.029]) Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
8–5000 µg/plate Negative2 (Creutziger, 1989)  
Valid. GLP study containing sufficient details. 
Result is considered as valid. 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate 
(667 µg/plate)7 
Negative2 (Florin et al., 1980)  
Insufficient validity (spot test, not according to 
OECD guideline, methods and results 
insufficiently reported). 
(Citral [05.020]) Reverse mutation S. typhimurium TA98, 
TA100, TA97a, TA102 
5–700 µg/plate Negative2 (Gomes-Carneiro et al., 1998) 
 
Valid. Published non-GLP study containing 
sufficient details. Result is considered as valid. 
Reverse mutation S. typhimurium TA92, 
TA94, TA98, TA100, 
TA1535, TA1537 
Up to 100 µg/plate Negative4 (Ishidate et al., 1984) 
 
Valid. According to current guidelines.The study 
is considered valid. 
Reverse mutation S. typhimurium TA100 NR Negative2 (Lutz et al., 1982) Validity cannot be evaluated. One strain only, 
Concentrations tested not specified. no re-run of 
the test; no other data on experimental results or 
design apart from a description of the test 
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method. 
(Citral [05.020] continued) Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
1–160 µg/plate Negative2 (Zeiger et al., 1987)  
(NTP, 2003) 
Valid. Standard NTP study carried out according 
to US.EPA guidelines; result is considered valid. 
Mutation E. coli WP2uvrA (trp -) 13-100 µg/plate Negative (Yoo, 1986) 
 
Validity cannot be evaluated (study in Japanese). 
Sister chromatid 
exchange 
Chinese hamster ovary cells 0.289-40.2 µg/ml Positive2 (NTP, 2003) 
 
Valid. Standard NTP study carried out according 
to US EPA guidelines; result is considered valid. 
Chromosomal 
aberration 
Chinese hamster ovary cells 12.5-60.6 µg/ml Negative2 (NTP, 2003) 
 
Valid. Standard NTP study carried out according 
to US.EPA guidelines; result is considered valid. 
Chromosomal 
aberration 
Chinese hamster fibroblast 
cells 
Up to 30 µg/ml Negative3 (Ishidate et al., 1984) 
 
Limited validity (performed only in the absence 
of metabolic activation). 
Rec assay B. subtilis M45 and H17 17 µg/disk Negative (Oda et al., 1979) 
 
The test system used is considered inappropriate; 
insufficient validity. 
Rec assay B. subtilis M45 and H17 0.16, 0.32, 0.63 µl/disk  
(142, 284, 560 µg/disk)9 
1.25, 2.5 µl/disk 
(1110, 2220 µg/disk)9 
Negative 
 
Positive 
(Kuroda et al., 1984) 
 
Validity cannot be evaluated. Article in Japanese; 
with limited information in tables and abstract. 
Assay of limited relevance. 
Rec assay B. subtilis M45 and H17 < 2.5 µl/disk  
(< 2220 µg/disk)9 
Positive (Yoo, 1986) 
 
Validity cannot be evaluated (study in Japanese). 
Study of limited relevance. 
Induction of tumour 
suppressor protein p53 
(DNA damage) 
Mouse fibroblast cells 
(NTCT 929) 
10-30 µg/ml Positive (Duerksen-Hughes et al., 1999) 
 
The Induction of tumor suppressor protein p53 
may be considered as indicator for genotoxicity. 
Result is considered valid, however, it has only 
limited relevance. 
(Citronellal [05.021]) Reverse mutation S. typhimurium  
TA98, TA100, TA97a, 
TA102 
1-300 µg/plate Negative2 (Gomes-Carneiro et al., 1998) 
 
Valid. Published non-GLP study containing 
sufficient details. Result is considered as valid. 
Reverse mutation S. typhimurium  
TA98 and TA 100 
0.05-500 µg/plate Negative2 (Kasamaki et al., 1982) 
 
Limited validity (insufficiently reported; only two 
strains). 
Sister chromatid 
exchange 
Chinese hamster ovary cells 3.3-100 µmol/l 
(0.51–15.4 µg/ml) 
Negative3 (Sasaki et al., 1989) 
 
Limited valitity. Tested for enhancing effect on 
Mitomycin C. 
Chromosomal 
aberration 
Chinese hamster B241 cells 50 nmol/l  
(0.008 µg/ml) 
Positive2 (Kasamaki et al., 1982) 
 
Limited validity (limited documentation; results 
for only one test concentration reported; long 
incubation period of 24 hrs; unusual cell line). 
Rec assay B. subtilis  
M45 and H17 
17 µg/disk Negative (Oda et al., 1979) 
 
The test system used is considered inappropriate; 
insufficient validity. 
(3-Methylcrotonaldehyde [05.124]) Ames test 
(preincubation) 
S. typhimurium TA98, 
TA100 
 Positive2 (BASF, 1991) Validity cannot be evaluated. Article in Japanese; 
with limited information in tables and abstract. 
Assay of limited relevance. 
(9-Decenal1 [05.139]) Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, TA1538 
0.001-1 nl/plate (0.001-1 
µg/plate)  
Negative2 (Richold and Jones, 1980) Validity cannot be evaluated (study in Japanese). 
Study of limited relevance. 
(Oleic acid [08.013]) Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, TA1538, 
E. coli WP2uvrA 
1 - 5000 µg/plate Negative2 (Shimizu et al., 1985) The Induction of tumor suppressor protein p53 
may be considered as indicator for genotoxicity. 
Result is considered valid, however, it has only 
limited relevance. 
Ames assay S. typh. TA98, TA100, 
TA1535, TA1537 
1 - 333 µg/plate Negative2 (Mortelmans et al., 1986) Modified Ames, preincubation assay. 
Concentrations were selected based on a 
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preliminary experiment. The study is considered 
valid. 
Rec assay B. subtilis 100 - 1000 µg/plate Negative2 (Osawa and Namiki, 1982) The validity of this study is unclear. 
SCE test CH V79 2.5 - 10 µg/ml  Negative  (Kinsella, 1982) Not cytotoxic. The assay was only performed 
without metabolic activation. Doses were 
selected based on a preliminary assay. The study 
is considered valid. 
Chrom. abs. CH V79 2.5 - 10 µg/ml  Positive (Kinsella, 1982) There was an increase in numerical 
abnormalities, but not in breaks, not 
concentration dependent. No cytotoxicity was 
observed. The assay was only performed without 
metabolic activation. Doses were selected based 
on preliminary assay. The study is considered 
valid. 
6-TG resistance CH V79 1.0 µg/ml  Negative  (Kinsella, 1982) Not cytotoxic. Only one concentration level. The 
assay was only performed without metabolic 
activation. The validity of the study cannot be 
evaluated. 
(Methyl linoleate & Methyl linolenate (mixture) 
[09.646]) 
Ames (His+ reversion) 
assay 
S. typh. TA100, TA98, 
TA102, TA97, TA1537 
125 - 1000 µg/plate Negative2 (MacGregor et al., 1985) Tests were conducted with methyl linoleate and 
methyl linolenate separately. Both were negative. 
Doses were selected based on prelimary assay. 
The study is considered valid. 
3-Methyl-but-3-en-1-ol [02.176] Ames assay S. typh. TA98, TA100, 
TA1535, TA1537 
20 - 5000 µg/plate Negative2, 5  (BASF, 1989) The complete report for this study was not 
provided. The validity of this study cannot be 
evaluated. 
(2,6-Dimethyl-5-heptenal [05.074]) Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, TA1538 
Up to 3600 µg/plate Negative2 (Wild et al., 1983) Five concentrations tested. The study is 
considered valid. 
Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, TA1538 
Up to 50000 µg/plate Negative2 (Heck et al., 1989) No information concerning a possible cytotoxic 
effect nor on the number of concentrations tested. 
The test guidelines do not require more than 5 
mg/plate. The validity of this poorly reported 
study cannot be evaluated. 
UDS test Rat hepatocytes Up to 1000 µg/ml Negative2 (Heck et al., 1989) No information concerning the number of 
concentrations tested. The validity of this poorly 
reported study cannot be evaluated. 
(Geranyl formate [09.076]) Rec assay B. subtilis 18 µg/disk  Negative (Oda et al., 1979) From english abstract. Only one dose level is 
mentioned in a table. The validity of the study is 
unclear. 
(Geranyl acetate [09.011]) Ames assay S. typh., TA98, TA100, 
TA1535  
Up to 2000 µg/plate  Negative  (Heck et al., 1989) No information concerning a possible cytotoxic 
effect nor on the number of concentrations tested. 
The validity of this poorly reported study cannot 
be evaluated.  
Ames assay S. typh., TA98, TA100, 
TA1535, TA1537 
1 - 3333 µg/plate  Negative (Mortelmans et al., 1986) Modified Ames, preincubation assay. Doses were 
selected based on preliminary assay. The study is 
considered valid. 
Rec assay B. subtilis 17 µg/disk  Negative  (Oda et al., 1979) From english abstract. Only one dose level is 
mentioned in a table. The validity of this study is 
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unclear. 
Rec assay B. subtilis Up to 20 µl/disk  Negative  (Yoo, 1986) From english abstract. No information concerning 
the number of doses tested. The validity of this 
study cannot be evaluated. 
Gene mutation Mouse; L5178Y TK+/-  Up to 100 µg/ml 
Up to 78 µg/ml 
Negative3;  
Positive4 (weak) 
(Heck et al., 1989) The validity of this poorly reported study cannot 
be evaluated. 
Gene mutation Mouse; L5178Y TK+/-  18.3 µg/ml Negative3;  
Positive4 
(Tennant et al., 1987) Detailed information on this study was not 
provided. The article includes a table presenting 
the results of different genotoxicity and 
carcinogenicity tests performed with several 
compounds.  
SCE test CHO cells 45 - 80 µg/ml;  
50 - 299 µg/ml 
Positive (weak)3;  
Positive (weak) or 
negative4  
(Galloway et al., 1987) Positive results, without metabolic activation, 
were observed at cytotoxic concentrations. Doses 
were selected based on preliminary assay. The 
study is considered valid. 
Chromosomal 
aberrations 
CHO cells  60 - 100 µg/ml;  
50 - 150 µg/ml 
Negative3;  
Negative4 
(Galloway et al., 1987) Doses were selected based on preliminary assay. 
The study is considered valid. 
UDS test Hepatocytes of F344 male 
rats 
NR Negative (Mirsalis et al., 1983) Only an abstract is available. The validity of this 
study cannot be evaluated. 
Inhibition of DNA 
synthesis 
CHO cells 113 µmole Negative (Meigs et al., 1995) Only one concentration level is mentioned. The 
validity of this study is unclear. 
UDS test Hepatocytes of F344 male 
rats 
Up to 100 nl/ml Negative (Heck et al., 1989) No information concerning the number of 
concentrations tested. The validity of this poorly 
reported study cannot be evaluated. 
Gene mutation Human lymphoblast TK6  Up to 320 µg/ml;  
Up to 500 µg/ml 
Negative3;  
Negative4 
(Caspary et al., 1988) Compound precipitation was the limiting factor 
for the maximum concentration. The study is 
considered valid. 
NR = Not Reported. 
1 A substance evaluated at the 61st JECFA meeting structurally related to candidate substances in FGE.06.  
2With and without metabolic activation.  
3Without rat liver S-9 activation.  
4With rat liver S-9 activation. 
5 3-Methyl-but-3-en-1-ol [FL-no: 02.176] (purity not reported) was tested in a bacterial reversion assay (Ames test) with Salmonella typhimurium strain TA1535, TA100, TA1537 and TA98 with and without exogenous metabolic activation (origin not 
reported), following the standard plate test and pre-incubation test. It is not reported whether a dose range-finding experiment was performed. The main experiments were conducted at a not reported number of doses from 20 to 5000 µg/plate. It is 
not reported whether the doses were tested in duplicate or triplicate. It is not reported the identity of the solvent. 
6 Polyploidy (8 %) was observed at the highest dose tested. 
7 Substance precipitated on the plate. 
8 Calculated using a relative molecular mass of 154.25. 
9 Calculated using a dentity of 0.888.  
Result:
Remarks: the available report mentions that the study was performed in accordance with the OECD Guideline 471 “Genetic Toxicology: Salmonella thyphimurium Reverse Mutation Assay”. The available report does not contain sufficient details nor 
is it published in a peer-reviewed journal. The validity of this study cannot be evaluated. 
 negative. Eventual bacteriotoxicity or precipitation is not reported.  
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(2,6-Dimethyl-5-heptenal 
[05.074]) 
Mouse micronucleus assay NMRI male and female 
mouse bone marrow  
NR 420 - 1540 
mg/kg 
Negative (Wild et al., 1983) Mice received a single dose. Dose levels were not 
justified. The validity of this study cannot be evaluated. 
Basc test D. melanogaster NR 25 mM Negative (Wild et al., 1983) Only one dose is mentioned. The validity of this study is 
unclear. 
(Geranyl acetate 
[09.011]) 
Mouse micronucleus assay B6C3F1 mouse bone 
marrow cells 
i.p. 450 - 1800 
mg/kg 
bw/day 
Negative (Shelby et al., 1993) Selection of maximum dose was justified. The study is 
considered valid. 
Unscheduled DNA synthesis F344 male rats 
hepatocytes 
Gavage NR Negative (Mirsalis et al., 1983) Only an abstract is available. The validity of this study 
cannot be evaluated. 
(Citral [05.020]) 
Micronucleus formation Mouse bone marrow 
erythrocytes 
Three intraperitoneal 
injections given at 24-h 
intervals; male mice only 
250, 500, or 
750 mg/kg 
bw1 
Negative (NTP, 2003)  
NTP study carried out according to US-EPA guideline. 
Result is considered as valid. 
Micronucleus formation Mouse peripheral blood 
erythrocytes 
Microencapsulated citral 
was administered in the 
diet for 14 weeks 
745, 1840, 
3915, or 8110 
mg/kg bw per 
day2(males) 
Negative (NTP, 2003)  
NTP study carried out according to a non-standard 
guideline; result is considered of limited validity. 
  Microencapsulated citral 
was administered in the 
diet for 14 weeks 
790, 1820, 
3870, or 7550 
mg/kg bw per 
day2 (females) 
Negative (NTP, 2003) 
NTP study carried out according to a non-standard 
guideline; result is considered of limited validity. 
(3-Methylcrotonaldehyde 
[05.124]) 
UDS Rat hepatocytes Oral administration 350 and 700 
mg/kg body 
weight 
Negative (BASF, 2001) Unpublished GLP study, carried out in accordance with 
OECD guideline no 486. The study is considered valid. 
Micronucleus test Mouse bone marrow 
erythrocytes 
Oral administration 175, 350 and 
750 mg/kg 
body weight 
Negative (BASF, 1992) Unpublished GLP study, carried out in accordance with 
OECD guideline (1991). The study is considered valid. 
NR = Not Reported. 
1 Three intraperitoneal injections given at 24-hours intervals; male mice only. 
2 Microencapsulated citral was administered in the diet for 14 weeks.  
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ANNEXES 
ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in 
schematic form in Figure I.1. The Procedure is based on the opinion of the Scientific Committee on 
Food expressed on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure 
developed by the Joint FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th 
meetings (JECFA, 1995; JECFA, 1996; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, 
structure-activity relationships, metabolism and, when needed, toxicity. One of the key elements in 
the Procedure is the subdivision of flavourings into three structural classes (I, II, III) for which 
thresholds of concern (human exposure thresholds) have been specified. Exposures below these 
thresholds are not considered to present a safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, 
which would suggest a low order of oral toxicity. Class II contains flavourings that have structural 
features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that 
have structural features that permit no strong initial presumption of safety, or may even suggest 
significant toxicity (Cramer et al., 1978). The thresholds of concern for these structural classes of 
1800, 540 or 90 µg/person/day, respectively, are derived from a large database containing data on 
subchronic and chronic animal studies (JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further 
steps address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products9
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
 (Step 2)?  
• are the flavourings or their metabolites endogenous10
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and 
B4)? 
 (Step A4)?  
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with 
the results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. 
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted 
such actions. 
 
                                                     
9 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated 
intakes of the flavouring agent” (JECFA, 1997a). 
10 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
 
 
  Substance would not be    
expected to be of safety concern Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95th percentile of reported usages (EFFA, 2002e). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004a). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes) and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry (EFFA, 2001b; EFFA, 2002a; EFFA, 
2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 2004; Flavour Industry, 2009) 
for 55 of the candidate substances in the present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.06Rev4 (EFFA, 
2001b; EFFA, 2002a; EFFA, 2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 2004; 
Flavour Industry, 2009) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.125 - 
- 
- 
- 
4 
10 
- 
- 
- 
- 
4 
10 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
4 
10 
4 
10 
- 
- 
- 
- 
02.138 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.152 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.170 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.175 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.176 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.195 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.201 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.222 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.229 1.03 - - - - 4.46 - 6.47 - - - - - - 1.3 1.03 - - 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.06Rev4 (EFFA, 
2001b; EFFA, 2002a; EFFA, 2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 2004; 
Flavour Industry, 2009) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
4.21 - - - - 18.16 - 20.26 - - - - - - 4.41 4,21 - - 
02.234 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
- 
- 
5 
25 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
05.061 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.082 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.137 0,005 
0,2 
0,01 
0,2 
0,001 
0,1 
0,005 
0,3 
- 
- 
0,001 
0,1 
0,005 
0,1 
0,01 
0,1 
0,005 
0,5 
0,01 
0,2 
- 
- 
- 
- 
0,5 
5 
- 
- 
0,01 
0,2 
0,001 
0,05 
0,01 
0,2 
- 
- 
05.143 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
- 
- 
- 
- 
2 
10 
4 
20 
3 
15 
2 
10 
05.170 22,29 
33,55 
- 
- 
173,78 
209,7 
- 
- 
- 
- 
950 
1000 
- 
- 
132,82 
177,55 
1 
2 
- 
- 
- 
- 
- 
- 
10 
10 
- 
- 
17,33 
27,72 
3 
6 
- 
- 
- 
- 
05.174 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.188 22,29 
33,55 
- 
- 
173,78 
209,7 
- 
- 
- 
- 
950 
1000 
- 
- 
132,82 
177,55 
1 
2 
- 
- 
- 
- 
- 
- 
10 
10 
- 
- 
17,33 
27,72 
3 
6 
- 
- 
- 
- 
05.203 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.217 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.218 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.220 0,05 
0,16 
- 
- 
0,08 
0,16 
0,04 
0,08 
- 
- 
0,1 
8 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0,05 
0,1 
0,08 
0,16 
0,1 
0,2 
- 
- 
05.226 - 
- 
0,08 
0,1 
0,1 
0,16 
0,1 
0,16 
0,1 
0,16 
0,18 
0,26 
0,05 
0,08 
0,05 
0,1 
0,1 
0,16 
- 
- 
- 
- 
- 
- 
0,1 
0,16 
- 
- 
0,1 
0,16 
0,08 
0,1 
- 
- 
- 
- 
08.074 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.100 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.102 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
09.341 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.368 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.377 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.562 0,5 
1 
- 
- 
- 
- 
0,5 
1 
- 
- 
1 
2 
- 
- 
1 
2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0,5 
1 
0 
0 
- 
- 
- 
- 
09.567 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.569 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.572 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.575 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.612 7 
35 
2 
10 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.638 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.640 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.643 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.672 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.673 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.831 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.838 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.854 9,3 
16 
- 
- 
- 
- 
- 
- 
- 
- 
14 
28,7 
- 
- 
22,7 
37 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
7,75 
14 
3,5 
7 
- 
- 
- 
- 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.06Rev4 (EFFA, 
2001b; EFFA, 2002a; EFFA, 2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 2004; 
Flavour Industry, 2009) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
09.855 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.871 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.872 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.884 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.885 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.897 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.898 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.928 7 
35 
5 
25 
10 
50 
7 
35 
7 
35 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.937 0,02 
0,4 
0,02 
0,4 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
2 
40 
0,4 
8 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
- 
- 
- 
- 
0,02 
0,4 
- 
- 
2 
40 
2 
40 
0,02 
0,4 
0,02 
0,4 
09.938 1 
5 
1 
5 
10 
50 
1 
5 
1 
5 
100 
500 
20 
100 
10 
50 
1 
5 
1 
5 
- 
- 
- 
- 
1 
5 
- 
- 
100 
500 
100 
500 
1 
5 
1 
5 
09.939 0,02 
0,4 
0,2 
0,4 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
2 
40 
0,4 
8 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
- 
- 
- 
- 
0,02 
0,4 
- 
- 
2 
40 
2 
40 
0,02 
0,4 
0,02 
0,4 
09.950 16 
20 
9 
11 
16 
20 
16 
20 
16 
20 
16 
20 
8 
10 
8 
10 
- 
- 
- 
- 
- 
- 
8 
10 
8 
10 
- 
- 
14 
18 
16 
20 
16 
20 
- 
- 
Two candidate substances [FL-no: 05.170 and 05.188] are also used in chewing gum in high levels, 
which is not covered by any of the above food categories. The normal use level for chewing gum is 
7000 mg/kg for both substances. For chewing gum, the intake estimate is 2 g/day. It is anticipated that 
all of the flavouring substance is released from the chewing gum. In the calculation of the mTAMDI 
of these candidate substances, use level figures in Table II.1.2 and the use level of chewing gum ((use 
level of chewing gum in mg/kg) x (2 g daily intake of chewing gum) = mg/person/day) are summed up 
to a total mTAMDI value of 69000 µg/person/day for both substances. These figures are presented in 
tables II.2.3 and 6.1. 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table II.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
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The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour 
Industry in the following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 
16 (EC, 2000) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes) and 
nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed 
in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the 55 flavouring substances in the 
present flavouring group, for which Industry has provided use and use levels (EFFA, 2001b; EFFA, 
2002a; EFFA, 2004c; EFFA, 2006b; EFFA, 2007a; EFFA, 2012a; Flavour Industry, 2004; Flavour 
Industry, 2009). The mTAMDI values are only given for the highest reported normal use levels (see 
Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(µg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.125 Undec-10-en-1-ol 2000 Class I 1800 
02.138 Dec-9-en-1-ol 3900 Class I 1800 
02.152 Hept-3-en-1-ol 3900 Class I 1800 
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02.170 Lavandulol 3900 Class I 1800 
02.175 2-Methylbut-3-en-1-ol 3900 Class I 1800 
02.176 3-Methylbut-3-en-1-ol 3900 Class I 1800 
02.195 Octa-3,5-dien-1-ol 3900 Class I 1800 
02.201 Pent-4-en-1-ol 3900 Class I 1800 
02.222 3-Pentenol-1 3900 Class I 1800 
02.229 (-)-3,7-Dimethyl-6-octen-1-ol 1400 Class I 1800 
02.234 3-Nonen-1-ol 3900 Class I 1800 
05.061 Oct-6-enal 1600 Class I 1800 
05.082 Dodeca-3,6-dienal 1600 Class I 1800 
05.137 Dec-4(cis)-enal 15 Class I 1800 
05.170 Neral 69000 Class I 1800 
05.174 Pent-4-enal 1600 Class I 1800 
05.188 trans-3,7-Dimethylocta-2,6-dienal 69000 Class I 1800 
05.203 9-Octadecenal 1600 Class I 1800 
05.217 5-Decenal 1600 Class I 1800 
05.218 16-Octadecenal 1600 Class I 1800 
05.220 4Z-Dodecenal 36 Class I 1800 
05.226 E-4-Undecenal 54 Class I 1800 
08.074 Dec-3-enoic acid 3200 Class I 1800 
08.100 4-Methylpent-3-enoic acid 3200 Class I 1800 
08.102 Non-3-enoic acid 3200 Class I 1800 
09.341 Citronellyl hexanoate 3900 Class I 1800 
09.368 Ethyl 4-methylpent-3-enoate 3900 Class I 1800 
09.377 Ethyl oct-3-enoate 3900 Class I 1800 
09.562 trans-3-Hexenyl formate 320 Class I 1800 
09.567 Hex-3-enyl decanoate 3900 Class I 1800 
09.569 Hex-3-enyl octanoate 3900 Class I 1800 
09.572 Hex-4-enyl acetate 3900 Class I 1800 
09.575 3-Hexenyl heptanoate 3900 Class I 1800 
09.612 Lavandulyl acetate 3900 Class I 1800 
09.638 Methyl dec-4-enoate 3900 Class I 1800 
09.640 Methyl deca-4,8-dienoate 3900 Class I 1800 
09.643 Methyl geranate 3900 Class I 1800 
09.672 Non-3-enyl acetate 3900 Class I 1800 
09.673 Non-6-enyl acetate 3900 Class I 1800 
09.674 Nona-3,6-dienyl acetate  Class I 1800 
09.831 Ethyl 3,7-dimethyl-2,6-octadienoate 3900 Class I 1800 
09.838 3-Hexenyl methyl carbonate 3900 Class I 1800 
09.854 cis-3-Hexenyl 2-methylbutanoate 6000 Class I 1800 
09.855 trans-3-Hexenyl hexanoate 3900 Class I 1800 
09.871 Citronellyl decanoate 3900 Class I 1800 
09.872 Citronellyl dodecanoate 3900 Class I 1800 
09.885 Hex-3-enyl hexadecanoate 3900 Class I 1800 
09.897 3-Methylbut-3-en-1-yl butyrate 3900 Class I 1800 
09.898 3-Methylbut-3-en-1-yl hexanoate 3900 Class I 1800 
09.928 trans-3-Hexenyl acetate 3900 Class I 1800 
09.937 Methyl (3Z)-hexenoate 800 Class I 1800 
09.938 6-Methyl-5-hepten-2-yl acetate 40000 Class I 1800 
09.939 Ethyl (3Z)-hexenoate 800 Class I 1800 
09.950 Z-5-Octenyl acetate 7900 Class I 1800 
05.143 2,5-Dimethyl-2-vinylhex-4-enal 1600 Class II 540 
09.884 Hex-3-enyl-2-ethylbutyrate 3900 Class II 540 
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ANNEX III: METABOLISM  
III.1. Introduction 
The present FGE consists of 56 straight- and branched-chain unsaturated primary alcohols, aldehydes, 
carboxylic acids and esters.  
Groups with 92 related supporting substances has been evaluated by the JECFA (JECFA, 1998a; 
JECFA, 1999a; JECFA, 2004b). 
III.2. Absorption, Distribution and Elimination 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
any of the candidate substances. However, data on absorption, distribution and excretion are available 
for the supporting substance citral [FL-no: 05.020]. 
In general, short chain (< C8) linear and branched-chain saturated/unsaturated aliphatic esters, 
alcohols, aldehydes and carboxylic acids are absorbed from the gastrointestinal tract (Dawson et al., 
1964; Gaillard and Derache, 1965; JECFA, 2000a). Long-chain carboxylic acids, such as linoleic acid 
and oleic acid, are readily absorbed from micelles in the jejunum, re-esterified with glycerol in 
chylomicrons and transported via the lymphatic system (Borgström, 1974). Radiolabeled linoleic and 
oleic acids have been administered by different routes to a variety of mammals and humans, 
demonstrating that fatty acid uptake occurs in all tissues, including the brain, by passive/facilitated 
diffusion and/or active transport (Abumrad et al., 1984; Dhopeshwarkar and Mead, 1973; Harris et al., 
1980; Schulthess et al., 2000). Large lipid soluble organic molecules are absorbed by passive 
diffusion across hydrophobic domains in cell membranes (Klaassen, 1996). 
Male Wistar rats and male LACA mice were given a single dose of 14C-labelled citral [FL-no 05.020] 
at dose levels of 5, 770 or 960 mg/kg bw for rats and 100 mg/kg bw for mice, by gavage. Citral 
underwent rapid absorption from the gastrointestinal tract and distribution throughout the body, 
independent of the dose administered. In both species, the radiolabel was excreted rapidly, with most 
being excreted within 24 hours, predominantly in the urine, but also in exhaled air (as 14CO2) and 
faeces. Excretion was essentially complete by 96 hours in rats and by 120 hours in mice (Phillips et 
al., 1976), as cited by JECFA (JECFA, 2004b).  
Male Fischer F344 rats were given citral labelled with 14C at the C1 and C2 positions in a single oral 
dose of 5, 50 or 500 mg/kg bw or an intravenous dose of 5 mg/kg bw. After 72 hours, the animals 
were sacrificed and tissues and excreta were analysed for radioactivity. Most radiolabel was excreted 
in the urine, faeces, and expired air as 14CO2 or [14C]citral within 24 hours, regardless of the dose or 
route of administration. At the lowest oral dose, 83 % of the radiolabel was recovered within 72 hours 
(51 % in urine, 12 % in faeces, 17 % as expired 14CO2, < 1 % as expired [14C]citral and 3 % in total 
tissues). Production of 14CO2 essentially ceased 12 hours after treatment and the amount of 14C found 
in any tissue was very small (< 2 %). This excretion profile did not change much with increasing oral 
dose, although both in this study and that of Phillips et al. (Phillips et al., 1976) oxidation to CO2 was 
somewhat greater at the lowest dose.  
After intravenous administration, citral was rapidly eliminated from the blood as less than 25 % of the 
administered dose remained in the blood 2 min. after administration. Within 5 min., no unmetabolised 
citral could be detected in the blood. Elimination of radioactivity from the blood followed three 
phases, a rapid first phase with an elimination half-life of 11 min., a slower intermediate phase with a 
half-life of 43 min. and a terminal phase with a half-life of 27 hours. Within 72 hours after treatment, 
79 % of the dose was recovered in urine (58 %), faeces (7 %), expired 14CO2 (8 %), expired 14C-citral 
(< 1 %) and tissues (6 %). Elimination was essentially complete within 24 hours. In bile duct-
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cannulated rats it was shown that approximately 27 % of an intravenous dose of 5 mg/kg bw was 
eliminated via the bile within 4 hours of dosing. No unmetabolised citral was detected in the bile. The 
somewhat greater faecal excretion (4 - 9 %) of citral by the oral route versus the intravenous route 
suggests that the oral dose was not completely absorbed (Diliberto et al., 1988), as cited by JECFA 
(JECFA, 2004b). 
The same authors conducted a study in which multiple doses were administered to ascertain whether 
citral could induce its own metabolism and thereby affect disposition and excretion. Male rats were 
treated orally with unlabelled citral at a dose of 5 mg/kg bw per day for 10 days, followed by 
treatment with [14C]citral in a single oral dose of 5 mg/kg bw for the study of disposition or a single 
intravenous dose of 5 mg/kg bw for the biliary excretion study. Repeated exposure increased biliary 
excretion to approximately 36 %, but did not affect the disposition pattern of citral in rats (Diliberto et 
al., 1988, as cited by JECFA, 2004b).  
From these studies it can be concluded that citral is rapidly absorbed, metabolised and excreted in the 
urine, faeces and expired air. There is evidence of enterohepatic circulation of citral metabolites. 
Tissue distribution is widespread, but there is no evidence of bioaccumulation. 
A more detailed discussion follows on metabolism of linear saturated/unsaturated primary alcohols, 
aldehydes and carboxylic acids and branched-chain unsaturated primary alcohols, aldehydes and 
carboxylic acids.  
A relevant discussion of the general aspects of metabolism for these types of substances may be found 
in FAO/WHO JECFA (JECFA, 1999a). 
III.3. Metabolism 
III.3.1. Hydrolysis of Esters in vitro 
Aliphatic esters are hydrolysed to the component alcohols and carboxylic acids as shown in Figure 
III.1. The carboxylesterase or esterase classes of enzymes, the most important of which are the beta-
esterases, catalyse ester hydrolysis (Heymann, 1980). In mammals, these enzymes occur throughout 
the body in most tissues (Heymann, 1980), but predominate in the hepatocytes (Heymann, 1980). The 
substrate specificity of beta-carboxylesterase isoenzymes has been correlated with the structure of the 
alcohol and carboxylic acid components (i.e. R and R’, see Figure III.1) (Heymann, 1980). 
 
R O
R'
R O
H
O O
H2O HOR'
carboxylesterase
 
Figure III.1 Ester hydrolysis 
 
In vitro hydrolysis studies of various esters have been performed with specific carboxylesterase 
isoenzymes isolated from pig and rat livers (Arndt and Krisch, 1973; Junge and Heymann, 1979). 
Different isoenzymes showed large differences in hydrolysis rates, pending on the chain length of the 
carboxyl and the alcohol moiety. The authors concluded that it appears reasonable to assume a 
cooperative and complementary function of the different carboxylesterase enzymes in the hydrolysis 
of the various esters (Junge and Heymann, 1979). 
In vitro hydrolysis data have been reported for structurally related esters of saturated linear and 
branched-chain carboxylic acids. Butyl acetate, ethyl butyrate, ethyl heptanoate, ethyl nonanoate and 
ethyl laurate were 10 to 37 % hydrolysed in artificial gastric juice (pH 1.2 at 37 °C) within two hours 
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and 72 to 100 % hydrolysed in artificial pancreatic juice (pH 7.5 at 37 °C) in one to two hours 
(Gangolli and Shilling, 1968). The half-lives of ethyl butyrate, ethyl heptanoate and ethyl laurate are 
in the range from 490 to 770 minutes in artificial gastric juice and from approximately 5.7 to 9.8 
minutes in artificial pancreatic juice (Longland et al., 1977). The half-lives of butyl acetate, isoamyl 
butyrate, ethyl hexanoate and ethyl heptanoate were 0.0491 to 0.492 seconds in rat liver tissue 
preparations and 0.0108 to 0.550 seconds in rat small intestinal mucosa (Longland et al., 1977). A 
concentration of 15 microlitre citronellyl acetate/l was reported to be completely hydrolysed within 
two hours by simulated intestinal fluid containing pancreatin (Grundschober, 1977). A concentration 
of < 18 microlitre citronellyl phenylacetate/l was reported to be 60 % hydrolysed within two hours 
(Grundschober, 1977). 
Generally hydrolysis appears to be faster in homogenates from rat liver and intestinal mucosa than in 
artificial gastric and pancreatic juices (Longland et al., 1977). 
An in vitro hydrolysis study on carbonate esters of alpha-, beta-naphtol and p-nitrophenol showed that 
carbonate esters are also hydrolysed by liver carboxyl esterase from human rat and mouse (Huang et 
al., 1993). 
In vitro hydrolysis data from studies with esters related to the candidate substances indicate that the 
esters included in this evaluation can be hydrolysed in the gut to yield the corresponding alcohols and 
carboxylic acids of the esters prior to absorption or in the liver following absorption (Gangolli and 
Shilling, 1968; Grundschober, 1977; Leegwater and van Straten, 1974; Longland et al., 1977). 
III.3.2. Metabolism of Linear Saturated/Unsaturated Primary Alcohols, Aldehydes and Carboxylic 
acids 
The alcohols formed via ester hydrolysis are subsequently oxidized to the corresponding aldehydes 
(formed by the oxidation of alcohols to their corresponding aldehydes), which are efficiently oxidized 
to the corresponding saturated/unsaturated carboxylic acids by high capacity enzyme pathways. 
Isoenzyme mixtures of NAD+/NADH-dependent alcohol dehydrogenase (ADH) obtained from human 
liver microsomes have been reported to catalyse oxidation of linear primary aliphatic 
saturated/unsaturated alcohols (Pietruszko et al., 1973). A comparison of the alcohol structure with 
enzyme binding affinity of ADH indicates that increased binding (lower Km) occurs with increasing 
chain length (i.e. C1 to C6) of the substrate and the presence of unsaturation. However, maximum 
reaction rates of oxidation are essentially constant regardless of the alcohol structure suggesting that 
alcohol-enzyme binding is not the rate limiting step for oxidation; rather, the activity of this enzyme 
appears to be dependent upon the lipophilic character of the alcohol substrate (Klesov et al., 1977). 
Similarly, aldehyde dehydrogenase (ALDH) present predominantly in hepatic cytosol exhibits broad 
specificity for oxidation of aldehydes (Eckfeldt and Yonetani, 1982; Feldman and Weiner, 1972). 
ALDH is more active for higher molecular weight aldehydes (Nakayasu et al., 1978). Xanthine 
oxidase and aldehyde oxidase also catalyse oxidation of a wide range of aldehydes to the 
corresponding unsaturated carboxylic acids (Beedham, 1988). 
At elevated levels of exposure and prior to oxidation to the corresponding carboxylic acid, the 
aldehyde may conjugate with sulphydryl groups such as glutathione to yield thiohemiacetals. 
Oxidation of low molecular weight aldehydes requires glutathione which implies that the substrate for 
ALDH-mediated oxidation may be the thiohemiacetal (Brabec, 1993).  
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Figure III.2 Metabolism of linear unsaturated carboxylic acid 
 
The resulting linear saturated/unsaturated carboxylic acids participate in normal fatty acid metabolism 
(Figure III.2). In this pathway, the carboxylic acid is condensed with coenzyme A (CoA) followed by 
catalytic dehydrogenation mediated by acyl CoA dehydrogenase (Voet and Voet, 1990). The resulting 
trans-2,3-unsaturated ester (trans-delta2-enoyl CoA) is converted to the 3-ketothioester, which 
undergoes beta-cleavage to yield an acetyl CoA fragment and a new thioester reduced by two carbons. 
Cleavage of acetyl CoA units will continue along the carbon chain until the position of unsaturation is 
reached. If the unsaturation begins at an odd-numbered carbon, acetyl CoA fragmentation will 
eventually yield a delta3-enoyl CoA, which cannot enter the fatty acid cycle until it is isomerised to 
the trans-delta2-enoyl CoA by enoyl CoA isomerase. If unsaturation begins at an even-numbered 
carbon, acetyl CoA fragmentation yields a delta2-enoyl CoA product, which is a substrate for further 
fatty acid oxidation. If the stereochemistry of the double bond is cis, it is isomerised to the trans 
double bond by the action of 3-hydroxyacyl CoA epimerase prior to entering the fatty acid oxidation 
pathway. Even-numbered carbon acids continue to be cleaved to acetyl CoA while odd-numbered 
carbon acids yield acetyl CoA and propionyl CoA. Acetyl CoA enters the citric acid cycle directly 
while propionyl CoA is transformed into succinyl CoA that then enters the citric acid cycle. 
Alternate minor metabolic pathways have been characterised for linear long-chain fatty acids and 
short-chain carboxylic acids containing unsaturation. While linoleic and oleic acids participate in 
beta-oxidation and normal fatty acid metabolism in most tissues (Masoro, 1977), they may undergo 
omega-oxidation in the liver and alpha-oxidation in the brain (Gibson et al., 1982; Wakil and Barnes, 
1971). 
Unsaturated short-chain carboxylic acids may be metabolised via saturation to yield a substrate that 
may participate in the fatty acid pathway. For example, the mechanism for oxidative metabolism of 4-
pentenoic acid has been studied in rat heart mitochondria. In vitro 4-pentenoic acid is converted to the 
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CoA thioester, which is dehydrogenated to yield the trans-2,4-pentadienoyl CoA (Figure III.3). Two 
enzyme-catalysed processes then compete for this conjugated thioester. In the first pathway, NADPH-
dependent enzyme-catalysed reduction of the delta4-alkene leads to trans-2-pentenoic acid. The 
second pathway involves beta-oxidation to yield 3-keto-4-pentenoyl CoA. In vitro hydrogenation 
predominates to yield trans-2-pentenoic acid, which then participates in normal fatty acid oxidation 
(Schulz, 1983). 
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Figure III.3 Metabolism of 4-pentenoic acid 
III.3.3. Metabolism of Branched-chain Unsaturated Primary Alcohols, Aldehydes and Carboxylic 
Acids 
Generally, branched-chain aliphatic alcohols are oxidized to the corresponding aldehydes, which in 
turn are oxidized to the corresponding carboxylic acids (Bosron and Li, 1980; Levi and Hodgson, 
1989). Branched-chain aliphatic alcohols and aldehydes have been reported to be substrates for ADH 
(Hedlund and Kiessling, 1969; Albro, 1975) and ALDH (Hedlund and Kiessling, 1969), respectively. 
As carbon chain length increases, the substrate-enzyme binding affinity with ADH (Pietruszko et al., 
1973) and the rates of ALDH-mediated oxidation also increase (Nakayasu et al., 1978). 
Similar to their saturated analogs, unsaturated branched-chain aliphatic alcohols and aldehydes are 
converted by the pathways cited above to the corresponding carboxylic acids, which participate in the 
normal fatty acid metabolism (Voet and Voet, 1990). 
Alternatively, they may undergo a combination of omega, omega-1 and beta-oxidation to yield polar 
metabolites, which are excreted as such or as glucuronic acid conjugates in the urine (Diliberto et al., 
1990). The principal metabolic pathways utilized for metabolisation of these branched-chain 
substances are determined primarily by four structural characteristics, carbon chain length, position of 
alkyl substituents, number of alkyl substituents and size of alkyl substituents. 
Short-chain (< C6) branched aliphatic carboxylic acids undergo beta-oxidation, preferentially in the 
longer chain. Beta-cleavage of the branched aliphatic carboxylic acids yields linear carboxylic acid 
fragments, which are sources of carbon in the fatty acid metabolism pathway or tricarboxylic acid 
cycle (Voet and Voet, 1990). For example, a single oral dose of 4.5, 45 or 450 mg/kg [1-14C]-
isobutyric acid given to male Charles River CD rats by gavage was rapidly eliminated in the breath as 
expired 14CO2. Within 24 hours of dosing, 77, 78, or 83 % of the 4.5, 45 or 450 mg/kg dose, 
respectively, was eliminated as CO2 (DiVincenzo and Hamilton, 1979). 
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Methyl methacrylate given to rats by gavage was also eliminated mainly as CO2 (Bratt and Hathway, 
1977). 
The hydrolysis of one candidate substance hex-3-enyl-2-ethylburtyrate [FL-no: 09.884] generates 2-
ethylbutyric acid [FL-no: 08.045], which has some teratogenic potential (see Section 9.3). Although 
the 2-ethyl-branched acid is resistant to beta-oxidation, it can be further conjugated with glucuronic 
acid or undergo omega-oxidation. However, the candidate substance [FL-no: 09.884] cannot be 
anticipated to be metabolised to an innocuous product. 
Terminal double bonds appear in eleven candidate substances [FL-no: 02.125, 02.138, 02.170, 
02.175, 02.176, 02.201, 05.143, 05.174, 09.612, 09.897 and 09.898]. Of these, six are unsaturated 
alcohols [FL-no: 02.125, 02.138, 02.170, 02.175, 02.176 and 02.201] two are unsaturated aldehydes 
[FL-no: 05.143 and 05.174] and three are esters [FL-no: 09.612, 09.897 and 09.898]. These double 
bonds may be oxidized to the corresponding epoxides. Epoxides are highly reactive molecules, due to 
the large strain associated with the three member ring structure and they react easily with nucleophilic 
sites of cellular macromolecules. For this reason, several aliphatic alkene-derived epoxides have been 
demonstrated to be carcinogenic (e.g. ethylene, isoprene, butadiene, glycidol) (Melnick, 2002). 
Alternatively, epoxides can be conjugated with glutathione (GSH) by glutathione S-tansferases 
(GSTs) or hydrolysed to diols by epoxide hydrolases (EHs). The latter two reactions can be 
considered to be detoxifications. 
It has been demonstrated that terminal double bonds may be oxidized at the double bond to give the 
corresponding epoxide or, alternatively, at the allylic carbon to give the allylic alcohol, as was 
demonstrated with 1-hexene with rat and human P450s (Chiappe et al., 1998). The ratio of 
epoxidation over allylic oxidation, as measured with different P450 isoforms (CYP) is ≥1, indicating 
that epoxide formation is generally favoured (Chiappe et al., 1998). Theoretically these pathways 
could occur with the candidate substances [FL-no: 02.125, 02.138, 02.175, 02.201, 05.143 and 
05.174]. 
In the same paper (Chiappe et al., 1998) it was demonstrated that the biotransformation of 2-methyl-1-
hexene proceeds exclusively via the epoxide, which was further hydrolysed by epoxide-hydrolase to 
the diol. This pathway might apply to the alcohols [FL-no: 02.170 and 02.176] and to the alcohol 
moiety of [FL-no: 09.612, 09.897 and 09.898]. 
However, the risk associated with the epoxidation of the terminal double bond of these candidate 
substances is expected to be low as: 
1) Epoxides can be metabolised by conjugation with glutathione or by epoxide-hydrolase 
mediated hydrolysis. 
2) The terminal double bonds are all present in molecules that have alcohol- or aldehyde 
functions at the end distal from the double bond, or that are alcohol moieties of esters. 
The alcohol- and aldehyde functions can be expected to be readily attacked by oxidation 
processes, ultimately yielding unsaturated carboxylic acids and also hydrolysis of the 
esters would yield the unsaturated alcohols, which will be oxidised to carboxylic acids. 
Biochemical attack of these carboxylic acids via e.g. beta-oxidation or conjugation with 
glucuronic acid is expected to be much more efficient and rapid than microsomal 
oxidation. 
Rats metabolised geraniol and citral (unsaturated branched-chain alcohol and aldehyde, respectively) 
via omega-oxidation and β-oxidation to yield a mixture of diacids and hydroxy acids, respectively 
(Diliberto et al., 1990; Chadha and Madyastha, 1984). Geraniol related terpenoid alcohols (citronellol 
and nerol) and the aldehydes (geranial, citronellal and neral) exhibit similar pathways of 
metabolisation in animals (Figure III.4). 
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Figure III.4 Metabolism of Geraniol in rats 
 
Male rats were given repeated oral doses of 800 mg [1-3H]-geraniol/kg bw by gavage daily for 20 
days. Five urinary metabolites were identified via two primary pathways. In one pathway, the alcohol 
is oxidized to yield geranic acid (3,7-dimethyl-2,6-octadieneoic acid), which is subsequently hydrated 
to yield 3,7-dimethyl-3-hydroxy-6-octenoic acid. In a second pathway, the alcohol undergoes omega-
oxidation mediated by liver cytochrome P-450 (Chadha and Madyastha, 1982) to yield 8-
hydroxygeraniol. Selective oxidation at C-8 yields 8-carboxygeraniol, which undergoes further 
oxidation to the principal urinary metabolite 2,6-dimethyl-2,6-octadienedioic acid (Chadha and 
Madyastha, 1984). 
In rats, citral, a mixture of the corresponding aldehyde of geraniol (geranial) and the aldehyde cis-
isomer (neral), is metabolised via similar alcohol and omega-oxidation pathways. In male Fisher 344 
rats given [1,2-14C]citral at a dose of 5 or 500 mg/kg bw by gavage, citral was rapidly metabolised and 
excreted as metabolites. The major metabolite identified in the bile was the glucuronide of geranic 
acid. In the urine of these rats, several carboxylic acids were identified (e.g. geranic acid, Hildebrandt 
acid (2,6-dimethyl-2,6-octadienedioic acid) and dihydro-Hildebrandt acid), resulting from oxidation 
of the aldehyde function or from omega-oxidation and further reduction and hydration of the 
unsaturation at C2 (Diliberto et al., 1990). Hepatic reduction of the aldehyde may precede oxidation 
pathways, as experiments in vitro revealed that citral is not oxidized by rat hepatic aldehyde 
dehydrogenase (ALDH) to the corresponding acids. In fact, citral was found to be a potent inhibitor of 
ALDH-mediated oxidation of acetaldehyde, and was reduced to the corresponding alcohols by rat 
hepatic alcohol dehydrogenase (ADH). These alcohols could then possibly undergo cytochrome P450-
mediated omega-hydroxylation, with the resulting diols being substrates for oxidation (Boyer and 
Petersen, 1991).  
A similar metabolic fate as that of geraniol and citral was found for nerol, citronellol, citronellal and 
citronellic acid. In rabbits given citronellol by gavage, dihydro-Hildebrandt acid and an alcohol 
precursor (8-hydroxy-3,7-dimethyl-6-octenoic acid) have been reported as urinary metabolites 
(Fischer and Bielig, 1940) as cited by JECFA 2004b). Rat lung microsomes have been shown capable 
of omega-hydroxylation of citronellol and nerol (Chadha and Madyastha, 1984 as cited by JECFA 
2004); a similar reaction has been reported for nerol with rabbit liver microsomes (Licht and Corsia, 
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1978 as cited by JECFA 2004b). In rabbits, citronellic acid was metabolized to dihydro-Hildebrandt 
acid (Asano and Yamakawa, 1950 as cited by JECFA 2004b). 
In rabbits, citronellal is metabolized to dihydro-Hildebrandt acid after oral administration. This 
indicates omega-oxidation. Three other metabolites were found in the urine of rabbits after oral 
administration, trans- and cis-menthane-3,8-diol and isopregol. These metabolites were the result of 
cyclization of citronellal, and accounted for < 10 % of the administered dose. The formation of trans- 
and cis-menthane-3,8-diol has been confirmed in vitro after 3 hours of incubation of citronellal with 
fresh gastric fluid isolated from male rabbits (Ishida et al., 1989 as cited by JECFA 2004b). 
Mono methyl substituted fatty acids are extensively metabolised to CO2 via beta-oxidative cleavage in 
the fatty acid pathway. If more than one methyl group is substituted in the lower as well as higher 
molecular weight acids or ethyl or propyl substituents are present, beta-oxidation is inhibited. In those 
cases metabolism involves direct conjugation of the acid with glucuronic acid or omega-oxidation 
followed by conjugation (Deuel, 1957; Williams, 1959). 
III.4. Summary and Conclusions 
In summary, it is anticipated that the esters in this group of candidate substances will undergo 
hydrolysis in the gastrointestinal tract, blood and liver to yield their corresponding aliphatic alcohols, 
aldehydes and carboxylic acids. Esters, aliphatic alcohols, aldehydes and carboxylic acids are 
expected to be absorbed from the gastrointestinal tract. Alcohols would be oxidized to their 
corresponding aldehydes and carboxylic acids and aldehydes would be oxidized to their 
corresponding carboxylic acids. The resulting aliphatic carboxylic acids undergoes complete 
metabolism to CO2 in the tricarboxylic acid cyclic and fatty acid pathway. 
The following substances [FL-no: 02.170, 02.175, 02.176, 02.229, 05.143, 05.170, 05.188, 09.341, 
09.612, 09.643, 09.831, 09.854, 09.871, 09.872, 09.884, 09.897, 09.898 and 09.938] are not 
completely oxidised to CO2 due to substitution in the beta-position or steric hindrance. However, 
these substances are expected to undergo oxidation reactions and to be excreted as such or after 
conjugation with glucuronic acid. Hex-3-enyl-2-ethylburtyrate [FL-no: 09.884], is hydrolysed to 2-
ethylbutyric acid and hex-3-enol, which can be further conjugated with glucuronic acid or undergo 
omega-oxidation. However, the candidate substance [FL-no: 09.884] cannot be anticipated to be 
metabolised to an innocuous product. 
The risk associated with possible epoxidation of the candidate substances with terminal double bond 
is expected to be low for two reasons. Epoxides can be metabolised by conjugation with glutathione 
or by epoxide-hydrolase mediated hydrolysis. The terminal double bonds in this group of flavourings 
are all present in molecules that have alcohol- or aldehyde functions at the end distal from the double 
bond, and the alcohol and aldehyde functions are expected to be metabolised to carboxylic acids prior 
to epoxidation of the double bond. 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
ADH  Alcohol dehydrogenase 
ALDH  Aldehyde dehydrogenase 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoA  Coenzyme A 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC  European Commission 
EFSA  The European Food Safety Authority 
EH  Epoxide hydrolase 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GSH  Glutathione 
GST  Glutathione S-transferase 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide 
NADH  Nicotinamide Adenine Dinucleotide, reduced form 
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
NOAEL No Observed Adverse Effect Level 
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NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
